Structural Basis for Allosteric Control of the SERCA-Phospholamban Membrane Complex by Ca^{2+} and cAMP-dependent Phosphorylation

Daniel K. Weber¹, Máximo Sanz-Hernández², U. Venkateswara Reddy¹, Songlin Wang¹, Erik K. Larsen², Tata Gopinath¹, Martin Gustavsson¹, Razvan L. Cornea¹, David D. Thomas¹ Alfonso De Simone³ and Gianluigi Veglia^{1,2,*}

¹ Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA

² Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USA

³ Department of Life Sciences, Imperial College London, South Kensington, London, SW7 2AZ, UK

* To whom correspondence should be addressed:

Gianluigi Veglia,
Department of Biochemistry, Molecular Biology & Biophysics,
University of Minnesota, 6-155 Jackson Hall, MN 55455.
Telephone: (612) 625-0758.
Fax: (612) 625-2163.
E-mail: vegli001@umn.edu.

Keywords: *Topological Allostery, membrane proteins, allosteric coupling, oriented solid-state NMR, bicelles.*

Phospholamban (PLN) is a mini-membrane protein that directly controls the cardiac Ca^{2+} -transport response to β -adrenergic stimulation, thus modulating cardiac output during the fight-or-flight response. In the sarcoplasmic reticulum membrane, PLN binds to the sarco(endo)plasmic reticulum Ca^{2+} -ATPase (SERCA), keeping this enzyme's function within a narrow physiological window. PLN phosphorylation by cAMP-dependent protein kinase A or increase in Ca^{2+} concentration reverses the inhibitory effects through an unknown mechanism. Using oriented-sample solid-state NMR spectroscopy and replica-averaged NMR-restrained structural refinement, we reveal that phosphorylation of PLN's cytoplasmic regulatory domain signals the disruption of several inhibitory contacts at the transmembrane binding interface of the SERCA-PLN complex that are propagated to the enzyme's active site, augmenting Ca^{2+} transport. Our findings address long-standing questions about SERCA regulation, epitomizing a signal transduction mechanism operated by posttranslationally-modified bitopic membrane proteins.

INTRODUCTION

Miniproteins are translated from small open reading frames of 100-300 nucleotides in length and constitute a neglected portion of the human proteome¹. Most miniproteins are membrane-embedded and act as regulators or ancillary proteins to enzymes or receptors²⁻⁴. Among the most critical miniproteins is phospholamban (PLN), a bitopic membrane polypeptide that regulates the function of the sarco(endo)plasmic reticulum Ca^{2+} -ATPase (SERCA) in cardiac muscle⁵. PLN directly controls cardiac output by maintaining SERCA's activity within a tight physiological window⁶. SERCA is a ten-transmembrane (TM) pump that promotes diastole by removing Ca^{2+} from the sarcoplasm and restoring high Ca^{2+} concentrations in the sarcoplasmic reticulum (SR) in preparation for the next systole⁶. As with other P-type ATPases, SERCA is fueled by ATP and cycles between two major conformational states *E1* and *E2*, of high and low Ca^{2+} -

47 affinity, respectively⁷. In cardiomyocytes, PLN is expressed in 4-fold molar excess of SERCA, suggesting
 48 that this endogenous regulator is permanently bound to the enzyme in a 1:1 stoichiometric ratio⁸. PLN
 49 binds the ATPase *via* intramembrane protein-protein interactions, lowering its apparent Ca^{2+} affinity and
 50 stabilizing the *E2* state of the pump^{6,9}. SERCA/PLN inhibitory interactions are relieved upon β -adrenergic
 51 stimulation, which unleashes cAMP-dependent protein kinase A (PKA) to phosphorylate PLN's cytoplas-
 52 mic domain at Ser16, enhancing Ca^{2+} transport by SERCA and augmenting heart muscle contractility¹⁰.
 53 Ablation, point mutations, or truncations of PLN have been linked to congenital heart disease⁹. Despite
 54 multiple crystal structures of SERCA alone⁷ and several structural studies of PLN free and bound to
 55 SERCA¹¹⁻¹³, the inhibitory mechanisms of PLN and its reversal upon phosphorylation or Ca^{2+} increase
 56 are still unknown. Mutagenesis data and molecular modeling suggested that SERCA regulation occurs
 57 through electrostatic and hydrophobic interactions between the helical transmembrane (TM) region of
 58 PLN and the binding groove of the ATPase formed by TM2, TM6, and TM9¹⁴. Upon phosphorylation, or
 59 binding SERCA, however, the helical TM domain of PLN does not undergo significant changes in sec-
 60 ondary structure¹⁵⁻¹⁷. As a result, X-ray crystallography¹⁶ and other structural techniques (*e.g.*, EPR or
 61 NMR) have not offered significant mechanistic insights into the regulatory process.

62 Here, we reveal the elusive signal transduction mechanism responsible for phosphorylation-in-
 63 duced activation of the SERCA/PLN complex using a combination of oriented-sample solid-state NMR
 64 (OS-ssNMR) spectroscopy and dynamic structural refinement by replica-averaged orientational-re-
 65 strained molecular dynamics simulations (RAOR-MD)^{18,19}. The analysis of anisotropic ^{15}N chemical
 66 shifts (CSs) and ^{15}N - ^1H dipolar couplings (DCs) of PLN alone and in complex with SERCA in magneti-
 67 cally aligned lipid bicelles unveiled collective topological changes of PLN's inhibitory TM domain in
 68 response to Ser16 phosphorylation. Specifically, the local perturbations of phosphorylation were alloster-

ically transmitted via an order-disorder transition of the juxtamembrane helical residues involved in several inhibitory interactions with SERCA. This intramembrane regulatory mechanism represents a potential paradigm of the structural basis of SERCA activity modulation by other regulins (*e.g.*, sarcolipin, myoregulin, DWORF, etc.)² in response to different physiological cues.

RESULTS

The TM domain of PLN undergoes a topological two-state equilibrium

In lipid membranes, PLN adopts an *L*-shaped conformation, with a membrane-adsorbed, amphipathic regulatory region (domain Ia, M1 to T17) connected by a short loop (Ile18 to Gln22) to a helical inhibitory region (domains Ib, Gln23 to Asn30; and domain II, Leu31 to Leu52), which crosses the SR membrane^{20,21}. In its storage form, PLN is pentameric²¹⁻²³ and de-oligomerizes into active *L-shape* monomers²⁰. The dynamic cytoplasmic region undergoes an order-disorder transition between tense (*T*) and relaxed (*R*) states, with the latter promoted by Ser16 phosphorylation^{15,17,24}. Upon binding SERCA, domain Ia transitions to a more-rigid and non-inhibitory bound (*B*) state, becoming more populated upon phosphorylation^{15,17}. How does Ser16 phosphorylation signal the reversal of inhibition to the TM region? Since the inhibitory TM region is ~ 45 Å away from Ser16 and ~ 20 Å from the SERCA's Ca²⁺ binding sites, we speculated that both phosphorylation (of PLN) and Ca²⁺ binding (to SERCA) must transmit conformational and topological changes across the membrane, thus allosterically modulating SERCA's function.

Residue-specific anisotropic NMR parameters such as CSs and DCs are exquisitely suited to describe topological transitions such as tilt, bend, and torque of TM proteins in lipid bilayers near-physiological conditions^{25,26}. Their analysis by OS-ssNMR requires that membrane-embedded proteins are uniformly oriented relative to the static magnetic field (**B**₀). Therefore, we reconstituted PLN free and in

complex with SERCA into magnetically aligned lipid bicelles²⁷. Since monomeric PLN is the functional form²⁸, we utilized a monomeric mutant of PLN devoid of TM cysteine residues²⁹. Both unphosphorylated (PLN^{AFA}) and phosphorylated (pPLN^{AFA}) variants of PLN were expressed recombinantly, while SERCA was purified from mammalian tissues³⁰. Since lipid bicelles orient spontaneously with the normal of the membrane ($\vec{n}$) perpendicular to $\mathbf{B}_0$, we doped the sample with Yb³⁺ ions to change the magnetic susceptibility and orient the lipid membranes with $\vec{n}$ parallel to $\mathbf{B}_0$. This expedient doubles the values of CSs and DCs and increases the resolution of the NMR spectra^{31,32}. Fig. 1a shows the 2D [¹⁵N-¹H] sensitivity-enhanced (SE)-SAMPI4³³ separated local field (SLF) spectra of free PLN^{AFA} and pPLN^{AFA}. Due to PLN's intrinsic conformational dynamics, the SLF spectra visualize only its TM region. The spectra display the typical wheel-like pattern diagnostic of a helical conformation for both the TM domains of PLN^{AFA} and pPLN^{AFA}. Residue-specific assignments were carried out on free PLN^{AFA} using a combination of a 3D SE-SAMPI4-PDSD spectrum³⁴, selective ¹⁵N labeled samples, and predictions from MD simulations³⁵ (Extended Data Table S1; Extended Data Fig. 1-3). To obtain PLN's topology in lipid bilayer, the assigned resonances were fit to idealized *Polar Index Slant Angle* (PISA) models extracting whole-body tilt (θ) and rotation or azimuthal (ρ) angles^{36,37}, which for free PLN^{AFA} was $\theta = 37.5 \pm 0.7^\circ$ and $\rho_{L31} = 201 \pm 4^\circ$, and for pPLN^{AFA} $\theta = 34.8 \pm 0.5^\circ$ and $\rho_{L31} = 201 \pm 4^\circ$, where ρ_{L31} is the rotation angle referenced to Leu31. Notably, the high resolution of the oriented SLF spectra of PLN^{AFA} show two distinct sets of peaks (Fig. 1b), with populations unevenly distributed. The average population of the minor state estimated from the normalized peak intensities is approximately $30 \pm 9\%$. Remarkably, the resonances of the minor population overlap almost entirely with those of pPLN^{AFA} (Fig. 1b), revealing a topological equilibrium in which the TM region of PLN interconverts between two energetically different orientations. We previously showed that PLN phosphorylation shifts the conformational equilibrium toward the *R* state¹⁷, releasing the interactions with the lipid membranes of domain Ia (Fig. 1c). Our OS-ssNMR data show that these

phosphorylation-induced effects propagate to the TM domains, shifting the topological equilibrium toward the less populated state.

PLN phosphorylation by PKA signals a rearrangement of the SERCA/PLN binding interface

To investigate how Ser16 phosphorylation allosterically affects the inhibitory TM binding interface, we reconstituted the SERCA/PLN complex in lipid bicelles and studied it by OS-ssNMR. The alignment of mammalian SERCA in bicelles was confirmed by cross-linking the most reactive cysteines with a trifluoromethylbenzyl (TFMB)-methanethiosulfonate (MTS) tag to probe its alignment by ^{19}F NMR (Fig. 1d and Extended Data Fig. 4). Five of the twenty-four cysteines of SERCA were uniquely labeled as monitored by solution NMR in isotropic bicelles ($q = 0.5$). In anisotropic bicelles ($q = 4.0$) and at low temperature, the ssNMR spectrum of ^{19}F -SERCA consists of a single unresolved ^{19}F resonance due to the rapid reorientation of the enzyme in the isotropic phase. Upon increasing the temperature, the ^{19}F -SERCA/bicelle complex orients with $\vec{n}$ perpendicular to $\mathbf{B}_0$, and the ^{19}F resonance becomes anisotropic as a triplet with 1.3 kHz dipolar coupling³⁸. Fig. 1e shows the 2D SLF spectra of PLN^{AFA} and pPLN^{AFA} in complex with SERCA. To maintain a functional and stable complex, we used a lipid-to-complex molar ratio of 2000:1, with PLN concentration 10 times less than in the SERCA free samples. Therefore, the signal-to-noise ratio in the oriented spectra is significantly reduced relative to the free forms. Nonetheless, the SLF spectra of both $\text{SERCA/PLN}^{\text{AFA}}$ and $\text{SERCA/pPLN}^{\text{AFA}}$ complexes show the wheel-like patterns typical of the α -helical domains with selective exchange broadening for resonances located at the protein-protein binding interface (Fig. 1f). The assigned peaks associated with the helical domain II were fit to the ideal PISA model, yielding $\theta = 33.2 \pm 1.2^\circ$ and $\rho_{\text{L31}} = 193 \pm 7^\circ$. Therefore, upon binding SERCA, PLN^{AFA} requires a distinguishable $-4.3 \pm 1.4^\circ$ change in tilt and a less significant $-8 \pm 8^\circ$ change in rotation. These error bounds factor the linewidths and variation associated with substituting ambiguous assignments into the PISA fitting (parentheses of Fig. 1e). Similarly, the PISA model for pPLN^{AFA} was fit to $\theta = 30.4 \pm$

1.1° and ρ_{L31} of $197 \pm 4^\circ$, suggesting that the topology of the TM domain requires adjustments of $-3.4 \pm 1.2^\circ$ and $-4 \pm 6^\circ$ to form a complex with the ATPase.

Reductions in the TM helix tilt angle, which accompanied phosphorylation and complex formation, also coincided with a dramatic broadening of peaks in the cluster of isotropic resonances around 140 ppm (Fig. 1e). These resonances are attributed to the dynamic domain Ib residues, and their disappearance is consistent with SERCA binding, which requires the unwinding of the juxtamembrane region, and a concomitant reduction of the tilt angle to re-establish hydrophobic matching with the thickness of the lipid bilayer^{13,17}. Therefore, for free and bound PLN, we find that communication between cytoplasmic and intramembrane environments is transduced via domain Ib dynamics. Analysis of the SLF spectra also shows that phosphorylation of PLN at Ser16 restores the intensities of most resonances except for those at the upper binding interface (*i.e.*, Asn30, Leu31, Asn34, and Phe41). These spectral changes suggest a reorganization of PLN-SERCA packing interactions, rather than a complete dissociation of the complex, consistent with prior MAS-ssNMR, EPR, and FRET measurements^{13,17,39,40}.

Dynamic structural refinement of the SERCA-PLN complexes

To determine the structural ensembles of the SERCA/PLN^{AFA} and SERCA/pPLN^{AFA} complexes, we incorporated the data from our experimental measurements into RAOR-MD samplings^{18,19}. This dynamic refinement methodology employs full atomic MD simulations in explicit lipid membranes and water and utilizes restraints from sparse datasets to generate experimentally-driven structural ensembles. As starting coordinates for our samplings, we used the X-ray structure of E2-SERCA/PLN, where a super-inhibitory mutant of PLN was used to stabilize the complex for crystallization¹⁶. We docked the TM domains of PLN^{AFA} using restraints obtained from chemical cross-linking experiments for both cytoplasmic and luminal sites^{14,42,43} (Extended Data Fig. 5a). The dynamic cytoplasmic region (loop and domain Ia), which was not resolved in the crystal structure, was held in proximity to the nucleotide-binding (N) and phosphorylation (P) domains of SERCA using upper boundary restraints from paramagnetic relaxation enhancements (PRE) obtained from MAS-ssNMR¹⁷. Additionally, CSs and DCs from OS-ssNMR were applied to the TM region as ensemble-averaged restraints across eight replicas. The resulting structural ensembles were in excellent agreement with all the available experimental data for both complexes. The overall profile of the average pairwise distances for residues in domain Ia and loop to the spin-label at Cys674 matches the PRE measurements, with the minimal distance (*i.e.*, maximum PRE effect) observed for PLN-Tyr6 (Extended Data Fig. 5b,c). Similarly, back-calculated CS and DC values for PLN^{AFA} and pPLN^{AFA} were in excellent agreement with experiments (Extended Data Fig. 5d). Average back-calculated tilt angles of 32.8° and 30.4° for PLN^{AFA} and pPLN^{AFA}, respectively, matched PISA fits to experimental values (Extended Data Fig. 5e,6). All pairwise distances between previously reported cross-linkable positions^{14,42-44} were distributed within acceptable ranges (Extended Data Fig. 5f). Although not used as an initial docking restraint, cytoplasmic residues PLN Lys3 and SERCA Lys397 were also partially distributed within a distance consistent with previously reported cross-linking⁴⁵.

190 To assess the SERCA/PLN complexes' conformational landscape, we used principal component
 191 analysis (PCA). PCA identified a combined opening of the cytoplasmic headpiece involving a hinge-like
 192 displacement of the N domain and rotation of the A domain away from the P domain (PC1) and planar
 193 rotations separating the N and A domains (PC2) (Fig. 2a,b, Extended Data Fig. 7, Extended Data Movie
 194 1). These motions differentiate the *E1* and *E2* states of SERCA, as shown by the projections of crystal
 195 structures onto the PCA map (Fig. 2c,d). The SERCA/PLN^{AFA} complex spans four distinct clusters, while
 196 the SERCA/pPLN^{AFA} complex spans eight (see Extended Data Fig. 8 for representative structures). When
 197 bound to PLN^{AFA}, SERCA mostly retains the compact *E1*-like headpiece present in the crystal structure
 198 and interconverts with equal frequency between a highly compact cluster (3) resembling nucleotide-bound
 199 *E1* states and a cluster (1) intermediate toward the *E2* states, which exhibits a partial opening of the A and
 200 N domains caused by breaking of the salt bridges involving Arg139-Asp426/Glu435 and Lys218-Asp422.
 201 Albeit biased along the *E1* coordinate of PC2, similar states were present for pPLN^{AFA}, but the interaction
 202 of pSer16 with Arg604 weakens the Asp601-Thr357 and Arg604-Leu356 hydrogen bonds at the hinge of
 203 the N and P domains, leading to four additional open states (clusters 5 to 8). Separate clusters correspond
 204 to successive breakages of interdomain hydrogen bonds in the headpiece. Salt bridges between PLN-Ser16
 205 to SERCA-Arg460 and PLN-Arg14 to SERCA-Glu392 were also found to stabilize these open states
 206 (Extended Data Fig. 9). These open states resemble off-pathway crystal structures solved for the Ca₂*E1*
 207 state observed in the absence of nucleotide^{7,46,47}. For all clusters, the binding interactions near the Ser16
 208 position were more persistent for pPLN^{AFA} than PLN^{AFA} (Fig. 2e,f, Extended Data Fig. 8).

Fig. 2: Conformational ensembles and energy landscapes of the SERCA/PLN^{AFA} and SERCA/pPLN^{AFA} complexes. **a**, **b**, Depiction of headpiece movements associated with the first (**a**) and second (**b**) principal components. Structures with the highest PC values are shown as transparent black. **c**, **d**, PCA histograms of SERCA/PLN^{AFA} (**c**) and SERCA/pPLN^{AFA} (**d**) structural ensembles with projections of crystal structures in various states: Ca₂E1-ATP^{48,49}, Ca₂E1~P-ADP⁴⁹⁻⁵¹, Ca₂E1⁴⁶, E1-SLN⁵², E2-PLN¹⁶, E2P^{50,53}, E2~P^{50,53,54}, and E2⁵⁵. Clusters are numbered. **e**, **f**, Top 20 most representative structures of PLN^{AFA} (**e**, cluster 1) and pPLN^{AFA} (**f**, cluster 2) bound to SERCA from the most representative state.

From the analysis of the structural ensembles of the two complexes, it emerges that the relief of inhibition (i.e., activation) occurs via a rearrangement of the intramembrane contacts between the TM region of pPLN^{AFA} and SERCA, with a reconfiguration of electrostatic interactions near the phosphorylation site and a disruption of packing at the protein-protein interface (Fig. 3a,b). The interactions between

the cytoplasmic regions are transient and highly dynamic, resembling the conformational ensembles of intrinsically disordered complexes⁵⁶. For both complexes, we observe persistent interactions between PLN-Glu2 and SERCA-Lys365, PLN-Glu19, and SERCA-Lys328, and to a lesser extent PLN-Lys3 and SERCA-Asp399 and PLN-Tyr6 and SERCA-Asp557. For PLN^{AFA}, however, the arginine residues (Arg9, Arg13, and Arg14) interact transiently with SERCA-Glu606, while for pPLN^{AFA}, the phosphate group at Ser16 interacts strongly with SERCA-Arg604 and SERCA-Lys605. Interestingly, we detected the formation of intramolecular salt-bridges between the phosphate of Ser16 and PLN-Arg9, PLN-Arg13, and PLN-Arg14, causing domain Ia to adopt a compact conformation as previously suggested by fluorescence data^{57,58} (Extended Data Table 2, 3). These cytoplasmic protein-protein interactions destabilized PLN's domain Ib and consequently severed inhibitory intermolecular contacts with SERCA's TM helices involving Gln23-Leu321/Arg325 (M4), Lys27-Phe809 (M6) and Asn30-Trp107 (M2), while the intermolecular contacts involving domain II are mostly retained (Fig. 3a and Extended Data Fig. 10). In fact, hydrophobic substitutions within domain Ib have been identified as hotspots for engineering super-inhibitory PLN mutants (*i.e.*, Asn/Lys27Ala and Asn30Cys), which exhibit stable helical structure well into the loop domain^{16,59,60}. Importantly, these structural ensembles capture the order-disorder dynamics of domain Ib resonances observed in the OS-ssNMR spectra and suggested by previous NMR and EPR studies⁶¹. Destabilization and detachment of this region is consistent with the reappearance of exchange-broadened interfacial resonances of domain II paralleled by broadening of the resonances of the dynamic domain Ib in the SLF spectra of the SERCA/pPLN^{AFA} complex (Fig 1e). The interactions of domain Ia (Arg13-Ser16) and inhibitory contacts of domain Ib (at Lys27) with SERCA appear to be mutually exclusive (Fig. 3c-f). In both complexes, the electrostatic interactions of PLN-Arg13, PLN-Arg14, or PLN-pSer16 with

the SERCA's Arg604-Glu606 stretch cause the detachment of PLN's domain Ib and the consequent weakening of the inhibitory interaction (Fig. 3c-g). This illustrates the regulatory role of the *B* state of PLN for relieving inhibition and the superinhibitory activity of domain Ia-truncated PLN¹⁷.

Fig. 3. Mechanism for reversal of PLN inhibition by phosphorylation. **a**, Ensemble-averaged per-residue structural analysis (upper panel) and intermolecular contact profiles (lower panel). A contact is defined when any PLN atom comes within 3.5 Å of any SERCA atom for any given frame. **b**, Spider plot of pairwise electrostatic interactions between cytoplasmic residues and SERCA in RAOR-MD conformational ensembles. **c**, **d**, 2D Histograms correlating the distances between the cytoplasmic binding interfaces, defined by the center of masses of Arg14 to Ser16 of PLN and Arg604 to Glu606 of SERCA, to the inhibitory intermolecular contacts of PLN Lys27 for the SERCA/PLN^{AFA} (**c**) and SERCA/pPLN^{AFA} (**d**) ensembles. **e**, **f**, Corresponding 1D histograms for Lys27 contacts (**e**) and binding of the cytoplasmic domain (**f**). **g**, Disruption of the inhibitory TM pairwise interactions detected in the RAOR-MD conformational ensembles. Linewidths of the interhelical contacts are scaled to average contacts per frame for the non-phosphorylated complex and colored by the relative change observed with phosphorylation. Directions of the purple arrows exemplify clockwise or counterclockwise rotations of the TM domain of PLN during the trajectories.

257 **Phosphorylation disrupts correlated motions between PLN^{AFA} and SERCA's Ca²⁺ binding sites**

258 To assess the effects of PLN's phosphorylation on Ca²⁺ transport, we calculated the topological correla-
 259 tions of the TM's tilt angle fluctuations between PLN's and SERCA's TM helices (Fig. 4a-d). When
 260 PLN^{AFA} is bound to SERCA, we observe a dense network of correlated motions between PLN's TM region
 261 and the binding groove (TM2, TM6, and TM9), as well as a dense cluster of correlations involving TM3,
 262 TM4, TM5, TM6, and TM7. This allosteric coupling influences the Ca²⁺ binding sites' geometry, possibly
 263 reducing SERCA's Ca²⁺ binding affinity. In contrast, the analysis of the trajectories of the
 264 SERCA/pPLN^{AFA} complex displays only correlated motions between the TM of pPLN^{AFA} and the most
 265 proximal SERCA helices, with only a sparse network of correlations involving TM4, TM5, TM6, and
 266 TM8. Phosphorylation of PLN at Ser16 increases the electrostatic interactions with the cytoplasmic do-
 267 main of SERCA (*R* to *B* state transition, *i.e.*, disorder to order)¹⁷, and simultaneously weakens intramem-
 268 brane protein-protein interactions to uncouple the dynamic transitions of PLN from SERCA. The latter
 269 removes the structural hindrance of PLN's TM domain and augments Ca²⁺ transport (Fig. 4e,f).

Fig.4. PLN topological transitions are allosterically coupled to SERCA's Ca^{2+} binding sites. a, b, Correlation maps of motions between the TM topology of PLN^{AFA} (a) or pPLN^{AFA} (b) with the topology of the 10 TM domains of SERCA. c, d, Corresponding spider plots showing the density of correlations are displayed below. Green spheres mark positions of the calcium-binding sites. e, f, Snapshots of the SERCA/PLN^{AFA} (e) and SERCA/pPLN^{AFA} (f) complexes highlighting the transient interactions with the cytoplasmic region and loosened interactions with the TM region of SERCA.

Effects of Ca^{2+} ion binding to SERCA on PLN's topology

To assess the effects of Ca^{2+} , we performed SLF experiments on SERCA/PLN^{AFA} and SERCA/pPLN^{AFA} complexes in the *E1* state (Extended Data Fig. 11a-c). The addition of Ca^{2+} to the SERCA/PLN^{AFA} complex did not cause significant changes to the PLN topology ($\theta = 32.9 \pm 1.4^\circ$ and $\rho_{\text{L31}} = 199 \pm 4^\circ$). However, the reappearance (*i.e.*, sharpening) of several resonances in the spectra (*e.g.*, Phe32, Phe35/Leu42, and Ala36) indicates a rearrangement of the binding interface between the two proteins similar to phosphorylation's effect on the *E2* complex. A small topological change, however, was observed for the SERCA/pPLN^{AFA} complex, for which Ca^{2+} -binding induced a decrease of both tilt and rotational angles of $1.8 \pm 1.3^\circ$ and $10 \pm 7^\circ$, respectively ($\theta = 28.6 \pm 0.7^\circ$ and $\rho_{\text{L31}} = 187 \pm 6^\circ$). Due to the lack of X-ray structures, we were unable to carry out dynamic modeling of these complexes. However, these experimental results agree with our *E2*-SERCA models suggesting that a loss of inhibition, either from phosphorylation or Ca^{2+} binding, does not require an extensive structural and topological reconfiguration of PLN's domain II or complete dissociation of the complex.

DISCUSSION

OS-ssNMR spectroscopy revealed that the TM helix of PLN undergoes a topological equilibrium that is shifted upon phosphorylation, providing direct evidence of the allosteric coupling between the outer membrane regulatory and TM inhibitory regions. Our dynamic modeling of the SERCA/PLN complexes using experimental restraints shows that the structural disorder of the juxtamembrane domain Ib following Ser16 phosphorylation of PLN signals a slight topological change in the TM region that is sufficient to relieve its inhibitory function. This event involves allosteric effects between the inhibitory interactions of domain II of PLN and SERCA's core helices harboring the Ca^{2+} binding sites. In addition to the localized disruption of PLN domain Ib interactions with SERCA, phosphorylation and Ca^{2+} -binding signal a collective

switch of PLN's TM domain from an inhibitory to a non-inhibitory topology. The tilt angle reductions of PLN accompanying the relief of inhibition are easily identifiable from the OS-ssNMR spectra, while rotations are more subtle; nonetheless these topological changes are sufficient to disrupt critical inhibitory interactions.

Recent X-ray investigations and extensive computational studies showed that SERCA undergoes significant rocking motions throughout its enzymatic cycle⁶²⁻⁶⁴. These conformational transitions analyzed in the absence of PLN are highly concerted and cooperative, *i.e.*, the dynamics of the cytoplasmic head-piece of SERCA correlates with its TM domains^{63,64}. PLN (and other regulins)² wedges into the ATPase's binding groove and either correlate with the topological changes of SERCA's TM domains or interfere with its rocking motions leading to uncoupling of ATP hydrolysis and Ca²⁺ transport. PLN experiences significant changes in tilt angle (ranging from 28.6° to 37.5°), depending on both the conformational state of PLN and enzymatic state of SERCA. Therefore, these dynamic and topological transitions provide the mechanism to modulate TM protein-protein interactions, which can be tuned by posttranslational phosphorylation, O-glycosylation⁶⁵, and binding of ancillary proteins^{66,67}.

The structural and dynamic changes of PLN, detected by OS-ssNMR, resolves an ongoing controversy about the *subunit* vs. *dissociative* models proposed for SERCA regulation^{9,39,40,68,69}. The latter model speculates that the reversal of the inhibitory function of PLN is due to a complete dissociation of this regulin from the ATPase; but this is not supported by spectroscopic data either *in vitro* or *in cell*^{13,17,39,40,69}. On the other hand, the subunit model agrees well with all spectroscopic measurements, but it does not explain the reversal of inhibition caused by phosphorylation or the elevation of Ca²⁺ concentration. Our ssNMR-driven dynamic calculations clearly shows that topological and structural changes modify the interactions at the interface and are propagated to the distal Ca²⁺ binding sites.

Fig. 6 summarizes our proposed mechanistic model for allosteric control of SERCA by PLN's topological changes. We previously showed that PLN's cytoplasmic domain undergoes a three-state equilibrium (*T*, *R*, and *B*) in which the *T* and *R* states are inhibitory, while the *B* state is non-inhibitory¹⁷. Our new data show that, when bound to the *E2*-SERCA state, the TM region of PLN (domains Ib and II) remains locked into the ATPase's binding groove. An increase of Ca^{2+} concentration drives SERCA into the *E1* state and reconfigures the intramembrane binding interface to augment Ca^{2+} transport without significant topological changes to PLN. On the other hand, detectable topological changes occur upon PLN's phosphorylation, both at low and high Ca^{2+} concentrations, as its conformational equilibrium is shifted toward the non-inhibitory *B* state⁷⁰ and changes are transmitted across the SERCA/PLN interface to increase Ca^{2+} transport. In this framework, it is possible to explain how single-site disease mutations or deletion in domains Ia and Ib may lead to perturbations of intra- and extra-membrane protein-protein interactions that result in dysfunctional Ca^{2+} transport^{59,71,72}.

Fig. 5. Regulatory model of SERCA by PLN's phosphorylation and Ca^{2+} . PLN's cytoplasmic domain exists in equilibrium between three distinct populations in the presence of SERCA. The increase of Ca^{2+} ions causes significant shifts SERCA's

conformation toward the E1 state, while the topology of PLN is only slightly affected (top equilibrium). Phosphorylation of PLN at Ser16 signals more extensive topological changes with a reconfiguration of SERCA/PLN TM interactions both at low and high Ca^{2+} concentrations (bottom equilibrium), augmenting Ca^{2+} transport. Note that the T and R populations are not represented for clarity.

In conclusion, the structural dynamics and topological allostery identified for PLN may explain how bitopic miniproteins, despite their simple architecture, can fulfill diverse regulatory roles and how posttranslational modification at cytoplasmic sites may constitute switches for signal transduction across cellular membranes operated by single or multiple transmembrane domains⁷³. Several mini-membrane proteins regulate membrane-embedded enzymes or receptors¹. In the heart, phospholemman⁷⁴⁻⁷⁶, a member of the FXYD family, regulates the Na^+/K^+ -ATPase interacting via its transmembrane domain, with its regulatory interactions modulated by protein kinases A and C. Several regulins have also been recently found to control SERCA's isoforms in other tissues² and share similar topologies to PLN. They all bind at distal locations from the active sites (*e.g.*, ATP or ion channels) of enzymes, revealing possible hotspots for allosteric control by small molecules. Therefore, the characterization of the topological allosteric control of SERCA by PLN represents a first step in understanding how and why evolution has preserved these small polypeptides as a means to regulate the function of ATPases^{75,77} or other membrane transporters⁷⁸.

Acknowledgments

This work was supported by the National Institute of Health grants R01 GM064742 and R01 HL144100 to G.V. and R01HL139065 and R37AG026160 to D.D.T. and R.L.C. D.W. was supported by an American Heart Association Postdoctoral Fellowship (19POST34420009).

360 References

- 361 1 Andrews, S. J. & Rothnagel, J. A. Emerging evidence for functional peptides encoded by short
362 open reading frames. *Nature Reviews: Genetics* **15**, 193-204, doi:10.1038/nrg3520 (2014).
- 363 2 Anderson, D. M. *et al.* Widespread control of calcium signaling by a family of SERCA-inhibiting
364 micropeptides. *Science Signaling* **9**, ra119-ra119, doi:10.1126/scisignal.aaj1460 (2016).
- 365 3 Ma, J. *et al.* Discovery of human sORF-encoded polypeptides (SEPs) in cell lines and tissue.
366 *Journal of Proteome Research* **13**, 1757-1765, doi:10.1021/pr401280w (2014).
- 367 4 Slavoff, S. A. *et al.* Peptidomic discovery of short open reading frame–encoded peptides in human
368 cells. *Nature Chemical Biology* **9**, 59-64, doi:10.1038/nchembio.1120 (2013).
- 369 5 Tada, M., Ohmori, F., Yamada, M. & Abe, H. Mechanism of the stimulation of Ca²⁺-dependent
370 ATPase of cardiac sarcoplasmic reticulum by adenosine 3':5'-monophosphate-dependent protein
371 kinase. Role of the 22,000-dalton protein. *Journal of Biological Chemistry* **254**, 319-326 (1979).
- 372 6 Bers, D. M. Cardiac excitation–contraction coupling. *Nature* **415**, 198-205, doi:10.1038/415198a
373 (2002).
- 374 7 Dyla, M., Kjærgaard, M., Poulsen, H. & Nissen, P. Structure and Mechanism of P-Type ATPase
375 Ion Pumps. *Annual Review of Biochemistry* **89**, 583-603, doi:10.1146/annurev-biochem-010611-
376 112801 (2020).
- 377 8 Ferrington, D. A., Yao, Q., Squier, T. C. & Bigelow, D. J. Comparable levels of Ca-ATPase
378 inhibition by phospholamban in slow-twitch skeletal and cardiac sarcoplasmic reticulum.
379 *Biochemistry* **41**, 13289-13296, doi:10.1021/bi026407t (2002).
- 380 9 MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility.
381 *Nature reviews: Molecular cell biology* **4**, 566-577, doi:10.1038/nrm1151 (2003).
- 382 10 Chu, G. *et al.* A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating
383 its maximal cardiac responses to β -agonists. *Journal of Biological Chemistry* **275**, 38938-38943,
384 doi:10.1074/jbc.M004079200 (2000).
- 385 11 Segrest, J. P., De Loof, H., Dohlman, J. G., Brouillette, C. G. & Anantharamaiah, G. M.
386 Amphipathic helix motif: Classes and properties. *Proteins: Structure, Function, and*
387 *Bioinformatics* **8**, 103-117, doi:10.1002/prot.340080202 (1990).
- 388 12 James, Z. M., McCaffrey, J. E., Torgersen, K. D., Karim, C. B. & Thomas, D. D. Protein-protein
389 interactions in calcium transport regulation probed by saturation transfer electron paramagnetic
390 resonance. *Biophysical Journal* **103**, 1370-1378, doi:10.1016/j.bpj.2012.08.032 (2012).

- 391 13 Karim, C. B., Zhang, Z., Howard, E. C., Torgersen, K. D. & Thomas, D. D. Phosphorylation-
392 dependent Conformational Switch in Spin-labeled Phospholamban Bound to SERCA. *Journal of*
393 *Molecular Biology* **358**, 1032-1040, doi:10.1016/j.jmb.2006.02.051 (2006).
- 394 14 Toyoshima, C. *et al.* Modeling of the inhibitory interaction of phospholamban with the Ca²⁺
395 ATPase. *Proceedings of the National Academy of Sciences* **100**, 467-472,
396 doi:10.1073/pnas.0237326100 (2003).
- 397 15 Seidel, K. *et al.* Structural characterization of Ca²⁺-ATPase-bound phospholamban in lipid
398 bilayers by solid-state nuclear magnetic resonance (NMR) spectroscopy. *Biochemistry* **47**, 4369-
399 4376, doi:10.1021/bi7024194 (2008).
- 400 16 Akin, B. L., Hurley, T. D., Chen, Z. & Jones, L. R. The Structural Basis for Phospholamban
401 Inhibition of the Calcium Pump in Sarcoplasmic Reticulum. *Journal of Biological Chemistry* **288**,
402 30181-30191, doi:10.1074/jbc.M113.501585 (2013).
- 403 17 Gustavsson, M. *et al.* Allosteric regulation of SERCA by phosphorylation-mediated
404 conformational shift of phospholamban. *Proceedings of the National Academy of Sciences* **110**,
405 17338-17343, doi:10.1073/pnas.1303006110 (2013).
- 406 18 De Simone, A., Mote, K. R. & Veglia, G. Structural Dynamics and Conformational Equilibria of
407 SERCA Regulatory Proteins in Membranes by Solid-State NMR Restrained Simulations.
408 *Biophysical Journal* **106**, 2566-2576, doi:10.1016/j.bpj.2014.03.026 (2014).
- 409 19 Sanz-Hernández, M., Vostrikov, V. V., Veglia, G. & De Simone, A. Accurate Determination of
410 Conformational Transitions in Oligomeric Membrane Proteins. *Scientific Reports* **6**, 23063-23063,
411 doi:10.1038/srep23063 (2016).
- 412 20 Traaseth, N. J. *et al.* Structure and topology of monomeric phospholamban in lipid membranes
413 determined by a hybrid solution and solid-state NMR approach. *Proceedings of the National*
414 *Academy of Sciences* **106**, 10165-10170, doi:10.1073/pnas.0904290106 (2009).
- 415 21 Verardi, R., Shi, L., Traaseth, N. J., Walsh, N. & Veglia, G. Structural topology of phospholamban
416 pentamer in lipid bilayers by a hybrid solution and solid-state NMR method. *Proceedings of the*
417 *National Academy of Sciences* **108**, 9101-9106, doi:10.1073/pnas.1016535108 (2011).
- 418 22 Vostrikov, V. V., Mote, K. R., Verardi, R. & Veglia, G. Structural dynamics and topology of
419 phosphorylated phospholamban homopentamer reveal its role in the regulation of calcium
420 transport. *Structure* **21**, 2119-2130, doi:10.1016/j.str.2013.09.008 (2013).

- Mravic, M. *et al.* Packing of apolar side chains enables accurate design of highly stable membrane proteins. *Science* **363**, 1418-1423, doi:10.1126/SCIENCE.AAV7541 (2019).
- Gustavsson, M., Traaseth, N. J. & Veglia, G. Probing ground and excited states of phospholamban in model and native lipid membranes by magic angle spinning NMR spectroscopy. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1818**, 146-153, doi:10.1016/j.bbamem.2011.07.040 (2012).
- Opella, S. J. & Marassi, F. M. Structure Determination of Membrane Proteins by NMR Spectroscopy. *Chemical Reviews* **104**, 3587-3606, doi:10.1021/cr0304121 (2004).
- Das, N., Murray, D. T. & Cross, T. A. Lipid bilayer preparations of membrane proteins for oriented and magic-angle spinning solid-state NMR samples. *Nature Protocols* **8**, 2256-2270, doi:10.1038/nprot.2013.129 (2013).
- Sanders, C. R. & Landis, G. C. Reconstitution of Membrane Proteins into Lipid-Rich Bilayered Mixed Micelles for NMR Studies. *Biochemistry* **34**, 4030-4040, doi:10.1021/bi00012a022 (1995).
- Zvaritch, E. *et al.* The Transgenic Expression of Highly Inhibitory Monomeric Forms of Phospholamban in Mouse Heart Impairs Cardiac Contractility. *Journal of Biological Chemistry* **275**, 14985-14991, doi:10.1074/jbc.275.20.14985 (2000).
- Karim, C. B., Marquardt, C. G., Stamm, J. D., Barany, G. & Thomas, D. D. Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. *Biochemistry* **39**, 10892-10897, doi:10.1021/bi0003543 (2000).
- Stokes, D. L. & Green, N. M. Three-dimensional crystals of CaATPase from sarcoplasmic reticulum. Symmetry and molecular packing. *Biophysical Journal* **57**, 1-14, doi:10.1016/S0006-3495(90)82501-7 (1990).
- Prosser, R. S., Hunt, S. A., DiNatale, J. A. & Vold, R. R. Magnetically Aligned Membrane Model Systems with Positive Order Parameter: Switching the Sign of S_{zz} with Paramagnetic Ions. *Journal of the American Chemical Society* **118**, 269-270, doi:10.1021/ja953598x (1996).
- Prosser, R. S., Volkov, V. B. & Shiyanovskaya, I. V. Novel Chelate-Induced Magnetic Alignment of Biological Membranes. *Biophysical Journal* **75**, 2163-2169, doi:10.1016/S0006-3495(98)77659-3 (1998).
- Gopinath, T. & Veglia, G. Sensitivity enhancement in static solid-state NMR experiments via single and multiple-quantum dipolar coherences. *Journal of the American Chemical Society* **131**, 5754-5756, doi:10.1021/ja900096d (2009).

- 34 Mote, K. R. *et al.* Multidimensional oriented solid-state NMR experiments enable the sequential assignment of uniformly ¹⁵N labeled integral membrane proteins in magnetically aligned lipid bilayers. *Journal of Biomolecular NMR* **51**, 339-346, doi:10.1007/s10858-011-9571-8 (2011).
- 35 Weber, D. K. & Veglia, G. A Theoretical Assessment of the Structure Determination of Multi-Span Membrane Proteins by Oriented Sample Solid-State NMR Spectroscopy. *Australian Journal of Chemistry* **73**, 246-251, doi:10.1071/ch19307 (2019).
- 36 Denny, J. K., Wang, J., Cross, T. A. & Quine, J. R. PISEMA powder patterns and PISA wheels. *Journal of Magnetic Resonance* **152**, 217-226, doi:10.1006/jmre.2001.2405 (2001).
- 37 Marassi, F. M. & Opella, S. J. A Solid-State NMR Index of Helical Membrane Protein Structure and Topology. *Journal of Magnetic Resonance* **144**, 150-155, doi:10.1006/jmre.2000.2035 (2000).
- 38 Glaser, R. W., Sachse, C., Dürr, U. H. N., Wadhwani, P. & Ulrich, A. S. Orientation of the antimicrobial peptide PGLa in lipid membranes determined from ¹⁹F-NMR dipolar couplings of 4-CF₃-phenylglycine labels. *Journal of Magnetic Resonance* **168**, 153-163, doi:10.1016/j.jmr.2004.02.008 (2004).
- 39 Dong, X. & Thomas, D. D. Time-resolved FRET reveals the structural mechanism of SERCA-PLB regulation. *Biochemical and Biophysical Research Communications* **449**, 196-201, doi:10.1016/j.bbrc.2014.04.166 (2014).
- 40 Bidwell, P., Blackwell, D. J., Hou, Z., Zima, A. V. & Robia, S. L. Phospholamban binds with differential affinity to calcium pump conformers. *Journal of Biological Chemistry* **286**, 35044-35050, doi:10.1074/jbc.M111.266759 (2011).
- 41 De Simone, A. *et al.* Structures of the Excited States of Phospholamban and Shifts in Their Populations upon Phosphorylation. *Biochemistry* **52**, 6684-6694, doi:10.1021/bi400517b (2013).
- 42 Chen, Z., Akin, B. L., Stokes, D. L. & Jones, L. R. Cross-linking of C-terminal residues of phospholamban to the Ca²⁺ pump of cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain. *Journal of Biological Chemistry* **281**, 14163-14172, doi:10.1074/jbc.M601338200 (2006).
- 43 Chen, Z., Stokes, D. L., Rice, W. J. & Jones, L. R. Spatial and Dynamic Interactions between Phospholamban and the Canine Cardiac Ca²⁺ Pump Revealed with Use of Heterobifunctional Cross-linking Agents. *Journal of Biological Chemistry* **278**, 48348-48356, doi:10.1074/jbc.M309545200 (2003).

- 482 44 Jones, L. R., Cornea, R. L. & Chen, Z. Close Proximity between Residue 30 of Phospholamban
483 and Cysteine 318 of the Cardiac Ca²⁺ Pump Revealed by Intermolecular Thiol Cross-linking.
484 *Journal of Biological Chemistry* **277**, 28319-28329, doi:10.1074/jbc.M204085200 (2002).
- 485 45 James, P., Inui, M., Tada, M., Chiesi, M. & Carafoli, E. Nature and site of phospholamban
486 regulation of the Ca²⁺ pump of sarcoplasmic reticulum. *Nature* **342**, 90-92, doi:10.1038/342090a0
487 (1989).
- 488 46 Toyoshima, C., Nakasako, M., Nomura, H. & Ogawa, H. Crystal structure of the calcium pump of
489 sarcoplasmic reticulum at 2.6 Å resolution. *Nature* **405**, 647-655, doi:10.1038/35015017 (2000).
- 490 47 Jensen, A. M., Sorensen, T. L., Olesen, C., Moller, J. V. & Nissen, P. Modulatory and catalytic
491 modes of ATP binding by the calcium pump. *EMBO Journal* **25**, 2305-2314, doi:10.1038/sj.emboj.7601135
492 [pii]10.1038/sj.emboj.7601135 (2006).
- 493 48 Toyoshima, C. & Mizutani, T. Crystal structure of the calcium pump with a bound ATP analogue.
494 *Nature* **430**, 529-535, doi:10.1038/nature02680 (2004).
- 495 49 Sorensen, T. L., Moller, J. V. & Nissen, P. Phosphoryl transfer and calcium ion occlusion in the
496 calcium pump. *Science* **304**, 1672-1675, doi:10.1126/science.10993661672 [pii]
497 (2004).
- 498 50 Olesen, C. *et al.* The structural basis of calcium transport by the calcium pump. *Nature* **450**, 1036-
499 1042, doi:10.1038/nature06418 (2007).
- 500 51 Toyoshima, C., Nomura, H. & Tsuda, T. Lumenal gating mechanism revealed in calcium pump
501 crystal structures with phosphate analogues. *Nature* **432**, 361-368, doi:10.1038/nature02981
502 (2004).
- 503 52 Winther, A.-M. L. *et al.* The sarcolipin-bound calcium pump stabilizes calcium sites exposed to
504 the cytoplasm. *Nature* **495**, 265-269, doi:10.1038/nature11900 (2013).
- 505 53 Toyoshima, C., Norimatsu, Y., Iwasawa, S., Tsuda, T. & Ogawa, H. How processing of
506 aspartylphosphate is coupled to lumenal gating of the ion pathway in the calcium pump.
507 *Proceedings of the National Academy of Sciences* **104**, 19831-19836,
508 doi:10.1073/pnas.0709978104 (2007).
- 509 54 Bublitz, M. *et al.* Ion pathways in the sarcoplasmic reticulum Ca²⁺-ATPase. *Journal of Biological*
510 *Chemistry* **288**, 10759-10765, doi:10.1074/jbc.R112.436550 (2013).
- 511 55 Toyoshima, C. & Nomura, H. Structural changes in the calcium pump accompanying the
512 dissociation of calcium. *Nature* **418**, 605-611, doi:10.1038/nature00944 (2002).

- 513 56 Olivieri, C. *et al.* Multi-state recognition pathway of the intrinsically disordered protein kinase
514 inhibitor by protein kinase A. *eLife* **9**, 1-28, doi:10.7554/eLife.55607 (2020).
- 515 57 Li, J., Bigelow, D. J. & Squier, T. C. Phosphorylation by cAMP-Dependent Protein Kinase
516 Modulates the Structural Coupling between the Transmembrane and Cytosolic Domains of
517 Phospholamban. *Biochemistry* **42**, 10674-10682, doi:10.1021/bi034708c (2003).
- 518 58 Li, J., Xiong, Y., Bigelow, D. J. & Squier, T. C. Phospholamban Binds in a Compact and Ordered
519 Conformation to the Ca-ATPase. *Biochemistry* **43**, 455-463, doi:10.1021/bi035424v (2004).
- 520 59 Kimura, Y., Asahi, M., Kurzydowski, K., Tada, M. & MacLennan, D. H. Phospholamban Domain
521 Ib Mutations Influence Functional Interactions with the Ca²⁺-ATPase Isoform of Cardiac
522 Sarcoplasmic Reticulum. *Journal of Biological Chemistry* **273**, 14238-14241,
523 doi:10.1074/jbc.273.23.14238 (1998).
- 524 60 Akin, B. L., Chen, Z. & Jones, L. R. Superinhibitory Phospholamban Mutants Compete with Ca²⁺
525 for Binding to SERCA2a by Stabilizing a Unique Nucleotide-dependent Conformational State.
526 *Journal of Biological Chemistry* **285**, 28540-28552, doi:10.1074/jbc.M110.151779 (2010).
- 527 61 Gustavsson, M. *et al.* Lipid-mediated folding/unfolding of phospholamban as a regulatory
528 mechanism for the sarcoplasmic reticulum Ca²⁺-ATPase. *Journal of Molecular Biology* **408**, 755-
529 765, doi:10.1016/j.jmb.2011.03.015 (2011).
- 530 62 Norimatsu, Y., Hasegawa, K., Shimizu, N. & Toyoshima, C. Protein-phospholipid interplay
531 revealed with crystals of a calcium pump. *Nature* **545**, 193-198, doi:10.1038/nature22357 (2017).
- 532 63 Das, A., Rui, H., Nakamoto, R. & Roux, B. Conformational Transitions and Alternating-Access
533 Mechanism in the Sarcoplasmic Reticulum Calcium Pump. *Journal of Molecular Biology* **429**,
534 647-666, doi:10.1016/j.jmb.2017.01.007 (2017).
- 535 64 Rui, H., Das, A., Nakamoto, R. & Roux, B. Proton Countertransport and Coupled Gating in the
536 Sarcoplasmic Reticulum Calcium Pump. *Journal of Molecular Biology* **430**, 5050-5065,
537 doi:10.1016/j.jmb.2018.10.014 (2018).
- 538 65 Yokoe, S. *et al.* Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications
539 for diabetic cardiomyopathy. *Glycobiology* **20**, 1217-1226, doi:10.1093/glycob/cwq071 (2010).
- 540 66 Kranias, E. G. & Hajjar, R. J. The Phospholamban Journey 4 Decades After Setting Out for Ithaka.
541 *Circulation Research* **120**, 781-783, doi:10.1161/circresaha.116.310007 (2017).

- 542 67 Menzel, J. *et al.* 14-3-3 Binding Creates a Memory of Kinase Action By Stabilizing the Modified
543 State of Phospholamban. *Science signaling* **13**, eaaz1436-eaaz1436,
544 doi:10.1126/scisignal.aaz1436 (2020).
- 545 68 Mueller, B., Karim, C. B., Negrashov, I. V., Kutchai, H. & Thomas, D. D. Direct Detection of
546 Phospholamban and Sarcoplasmic Reticulum Ca-ATPase Interaction in Membranes Using
547 Fluorescence Resonance Energy Transfer. *Biochemistry* **43**, 8754-8765, doi:10.1021/bi049732k
548 (2004).
- 549 69 Martin, P. D., James, Z. M. & Thomas, D. D. Effect of Phosphorylation on Interactions between
550 Transmembrane Domains of SERCA and Phospholamban. *Biophysical Journal* **114**, 2573-2583,
551 doi:10.1016/j.bpj.2018.04.035 (2018).
- 552 70 Masterson, L. R. *et al.* cAMP-dependent protein kinase A selects the excited state of the membrane
553 substrate phospholamban. *J Mol Biol* **412**, 155-164, doi:10.1016/j.jmb.2011.06.041 (2011).
- 554 71 Fujii, J., Maruyama, K., Tada, M. & MacLennan, D. H. Expression and site-specific mutagenesis
555 of phospholamban. Studies of residues involved in phosphorylation and pentamer formation.
556 *Journal of biological chemistry* **264**, 12950-12955 (1989).
- 557 72 Toyofuku, T., Kurzydowski, K., Tada, M. & MacLennan, D. H. Amino Acids Glu2 to Ile18 in
558 the Cytoplasmic Domain of Phospholamban Are Essential for Functional Association with the
559 Ca²⁺-ATPase of Sarcoplasmic Reticulum. *Journal of Biological Chemistry* **269**, 3088-3094
560 (1994).
- 561 73 Bocharov, E. V. *et al.* Helix-helix interactions in membrane domains of bitopic proteins:
562 Specificity and role of lipid environment. *Biochimica et Biophysica Acta (BBA) - Biomembranes*
563 **1859**, 561-576, doi:10.1016/j.bbamem.2016.10.024 (2017).
- 564 74 Presti, C. F., Jones, L. R. & Lindemann, J. P. Isoproterenol-induced phosphorylation of a 15-
565 kilodalton sarcolemmal protein in intact myocardium. *Journal of Biological Chemistry* **260**, 3860-
566 3867 (1985).
- 567 75 Bers, D. M., Despa, S. & Bossuyt, J. Regulation of Ca²⁺ and Na⁺ in normal and failing cardiac
568 myocytes. *Annals of the New York Academy of Sciences* **1080**, 165-177,
569 doi:10.1196/annals.1380.015 (2006).
- 570 76 Teriete, P., Thai, K., Choi, J. & Marassi, F. M. Effects of PKA phosphorylation on the
571 conformation of the Na,K-ATPase regulatory protein FXYD1. *Biochimica et Biophysica Acta -*
572 *Biomembranes* **1788**, 2462-2470, doi:10.1016/j.bbamem.2009.09.001 (2009).

- 573 77 Singh, D. R. *et al.* Newly Discovered Micropeptide Regulators of SERCA Form Oligomers but
574 Bind to the Pump as Monomers. *Journal of Molecular Biology* **431**, 4429-4443,
575 doi:10.1016/j.jmb.2019.07.037 (2019).
- 576 78 Makarewich, C. A. The hidden world of membrane microproteins. *Experimental Cell Research*
577 **388**, 111853-111853, doi:10.1016/j.yexcr.2020.111853 (2020).
- 578

Structural Basis for Allosteric Control of the SERCA-Phospholamban Membrane Complex by Ca²⁺ and cAMP-dependent Phosphorylation

Daniel K. Weber¹, Máximo Sanz-Hernández², U. Venkateswara Reddy¹, Songlin Wang¹, Erik K. Larsen², Tata Gopinath¹, Martin Gustavsson¹, Razvan L. Cornea¹, David D. Thomas¹ Alfonso De Simone³ and Gianluigi Veglia^{1,2,*}

¹ Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA

² Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USA

³ Department of Life Sciences, Imperial College London, South Kensington, London, SW7 2AZ, UK

* To whom correspondence should be addressed:

Gianluigi Veglia,
Department of Biochemistry, Molecular Biology & Biophysics,
University of Minnesota, 6-155 Jackson Hall, MN 55455.
Telephone: (612) 625-0758.
Fax: (612) 625-2163.
E-mail: vegli001@umn.edu.

Methods

Expression, purification, and phosphorylation of PLN^{AFA}. Uniformly ¹⁵N-labelled PLN^{AFA} was expressed as a soluble fusion with maltose binding protein (MBP) as reported previously¹, with minor modifications. Freshly transformed *E. coli* Codon Plus (Invitrogen) cells were used to inoculate overnight LB cultures, which were subsequently centrifuged and resuspended into M9 minimal media (¹⁵NH₄Cl as the sole nitrogen source) at an OD₆₀₀ of ~0.7. Cultures were grown at 30°C to OD₆₀₀ 1.0 then induced with 1 mM IPTG over 20 h to a final OD₆₀₀ of 5. Cells (~6 g/L of M9) were stored at -20°C. Selectively ¹⁵N-labelled PLN was expressed from M9 media (free of NH₄Cl) with 125 mg/L of the respective ¹⁵N-amino acid, 300 mg/L of non-scrambling and 450 mg/L scrambling-prone ¹⁴N-amino acids². Reverse-labeled PLN was expressed in M9 minimal media (¹⁵NH₄Cl) with 1 g/L of the respective ¹⁴N-labeled amino acid. Induction times for selective and reverse labeling growths were reduced to 3 to 4 h to reduce scrambling.

For purification, cells were homogenized (Sorvall Omni Mixer) and lysed by sonification in 200 mL lysis buffer (20 mM sodium phosphate, 120 mM NaCl, 2 mM DTT, 1 mM EDTA, 0.1 mg/mL

lysozyme, 0.5 % glycerol, 0.5% Tween 20 and protease inhibitors, pH 7.3). The lysate was centrifuged (17,500 rpm, JA25.50 rotor, 4°C, 40 min) and supernatant loaded onto 30 mL bed volume of amylose resin. The resin was washed with buffer (20 mM sodium phosphate, 120 mM NaCl, pH 7.3) and eluted into 100 mL buffer including 50 mM maltose. Elution volumes were concentrated to ~50 mL and dialyzed overnight against 3 L of cleavage buffer (50 mM Tris-HCl, 2 mM β -mercaptoethanol, pH 7.3). All purification steps were done at 4°C and yielded up to 120 mg of fusion protein from 1 L M9 media.

To phosphorylate PLN^{AFA} at Ser16 (pPLN^{AFA}), the MBP fusion was dialyzed into 30 mM Tris-HCl, pH 7.5, followed by addition of 11x reaction buffer to reach 50 mM Tris-HCl, 10 mM MgCl₂, 0.05 mM PMSF, 1 mM NaN₃, 1 mM EDTA). The catalytic subunit of protein kinase A (PKA) was added at 1:1000 ratio to fusion protein, with 2 mM DTT, and the reaction started by addition of 2 mM ATP and incubation at 30°C for 3 h with gentle agitation.

MBP-PLN, either phosphorylated or non-phosphorylated, was cleaved with TEV protease and 2 mM DTT for 3 h at 30 °C to liberate insoluble PLN (Extended Data Fig. 12a), which was pelleted by centrifugation and dissolved into 10% SDS and 50 mM DTT at approximately 10 mg/mL then stored at -20 °C. PLN was further purified by HPLC using a Vydac 214TP10154 C4 column heated at 60 °C and eluted using H₂O/0.1% trifluoroacetic acid (TFA) and a linear gradient of isopropanol/0.1% TFA from 10 to 40% over 10 mins then to 80% over 50 min (2 mL/min flow rate). The protein was lyophilized. Complete phosphorylation of pPLN^{AFA} was confirmed by MALDI-MS (Extended Data Fig. 12b). The inhibitory activity of PLN^{AFA} against SERCA, and relieved inhibition of pPLN^{AFA}, in the DMPC/POPC (4:1) lipid bilayer composition used for NMR studies, was confirmed by a coupled enzyme assay³ (Extended Data Fig. 12c).

Preparation of oriented bicelle samples. Long-chain lipids DMPC (37.0 mg), POPC (10.4 mg) and PE-DTPA (0.9 mg; *i.e.*, 79.25:19.75:1.0 molar ratio) were aliquoted together from chloroform stocks (Avanti Polar Lipids), dried to a film with N₂ and residual solvent removed under high vacuum. The film was resuspended into 1 mL ddH₂O, freeze-thawed three times between liquid N₂ and a 40 °C water bath then lyophilized. DHPC (7.7 mg; 1:4 molar ratio, or $q = 4$, to long chain lipids) was prepared separately from a chloroform stock, dried and lyophilized from ddH₂O.

For bicelles containing only PLN, DHPC was dissolved into 250 μ L sample buffer (20 mM HEPES, 100 mM KCl, 1 mM NaN₃, 2.5% glycerol, pH 7.0), then used to solubilize PLN (2.5 mg) by

vortex. Separately, long-chain lipids were suspended into 250 μ L of buffer. PLN in DHPC and long-chain lipids, both pre-chilled in ice, were combined and vortexed while allowing the sample to reach room temperature, then placed back on ice. The process was repeated at least three times to fully solubilize long-chain lipids, which produced a completely transparent liquid at cold temperature (micelle phase) and transparent solid gel at room temperature (bicelle phase). The sample was placed on ice, brought to pH 4.2 with KOH, then concentrated to $\sim$ 180 μ L using a 0.5 mL 10 kDa MWCO centrifugal filter (Amicon) at 4°C. The solubility of PLN^{AFA} and pPLN^{AFA} was significantly diminished at higher pH. The sample was doped with 0.8 μ L of 1 M YbCl₃, corrected back to pH 4.2 with KOH, then loaded into a 5 mm flat bottom sample cell (New Era).

For bicelles containing the SERCA/PLN^{AFA} complexes, SERCA1a was purified from rabbit skeletal muscle as previously described⁴. SERCA was eluted from Reactive Red affinity resin at $\sim$ 0.5 mg/mL in SERCA, 0.1% C₁₂E₈, 1 mM CaCl₂, 1 mM MgCl₂, 20 mM MOPS, 20% glycerol, 8 mM ADP, 0.25 mM DTT, pH 7.00 and stored at -80°C. Protein concentration was determined by Pierce BCA Assay (Thermo Scientific) and activity confirmed by coupled-enzyme assays³. Immediately prior to use, SERCA (4 mg) was thawed at 4°C and combined with long-chain lipids (prepared as above, except with

Fig. 5: Effects of Ca²⁺ binding to SERCA on the topology of PLN and pPLN. a, b, 2D [¹⁵N-¹H] SE-SAMPI4 spectrum of PLN^{AFA} (a) and pPLN^{AFA} (b) bound to SERCA in the E1 form reconstituted into aligned lipid bicelles. PISA wheels for an ideal helix [(ϕ , ψ)=(-63°, -42°)] are superimposed. Equivalent spectra of the E2 form complexes are shown in grey. c, The conformational and topological effects of phosphorylation and Ca²⁺ binding to the SERCA/PLN^{AFA} complex.

molar PE-DTPA chelating lipid) solubilized into 1 mL of 4% C₁₂E₈ in sample buffer. The mixture was diluted to ~30 mL with sample buffer and stirred at 4°C for 30 min prior removal of C₁₂E₈ by adding 4 g of Bio-Beads SM-2 (Bio-Rad) in stages of 0.5, 0.5, 1 and 2 g with 15 min stirring between additions. Stirring continued overnight at 4°C. Bio-Beads were removed by a 25G syringe and the cloudy suspension of proteoliposomes centrifuged at (12,000 rpm, JA25.50 rotor, 4°C, 30 min). The pellet was resuspended into ~40 mL sample buffer and centrifuged once more to wash out residual elution buffer. The final pellet was resuspended with 250 µL sample buffer and fully solubilized by adding a 250 µL mixture of PLN^{AF}, or pPLN^{AF} (0.23 mg), in DHPC (adjusted to pH 7.0) with several cooling/heating cycles under vortex. The bicelle mixture (~1 mL) was centrifuged (13,400 rpm, Eppendorf F45-12-11 rotor, 4°C, 30 sec) to remove insoluble debris and the supernatant concentrated to ~200 µL using a 0.5 mL 10 kDa MWCO centrifugal filter (Amicon) at 4 °C. The sample was doped with 1.6 µL of 1 M YbCl₃ in four stages, correcting pH back to 7.0 with KOH at each addition. Sample buffer included 20 mM HEPES, 100 mM KCl, 1 mM NaN₃, 5 mM MgCl₂, 2 mM DTT, 2.5% glycerol, pH 7.0 with 4 mM EGTA or 5 mM CaCl₂ to stabilize *E2* or *E1* states, respectively. SDS-PAGE confirmed co-reconstitution of SERCA and PLN in the bicelles (Extended Data Fig 12d).

Synthesis of TFMB and tagging of SERCA. Trifluoromethylbenzyl (TFMB)-methanethiosulfonate (MTS) was synthesized analogously to our method previously reported for synthesizing a ¹³C-ethylmethanethiosulfonate tag^{5,6} with minor modifications. Briefly, 4-(trifluoromethyl)benzyl bromide (5 mmole), MTS (5 mmole) and KI (0.03 mmole) were dissolved into 2 mL of dimethylformamide and stirred under nitrogen for 16 h at 40°C.

For TFMB tagging, SERCA (8 mg) was thawed and dialyzed into 1 L of *E1*-state sample buffer (as above, but without DDT and including 0.25 mM C₁₂E₈) overnight at 4 °C. DMPC (25.2 mg) and POPC (7.1 mg), solubilized in 500 µL of 5% C₁₂E₈, was then added to dialyzed SERCA. Detergent was removed by stirring with 1 g Bio-Beads SM-2 for 1.5 h at 4°C and a further 30 min at room temperature. Proteoliposomes were removed from Bio-Beads with a 25G syringe and centrifuged (18,000 rpm, JA25.50 rotor, 4 °C, 40 min). The pellet was suspended into 120 µL buffer and solubilized by adding DHPC (*q* = 4 for oriented or *q* = 0.5 for isotropic bicelles). TFMB-MTS (200 mM in DMSO) was added to the bicelles at 5:1 molar excess and incubated at room temperature for 1 hour prior to concentrating to ~250 with a 0.5 mL 10 kDa MWCO centrifugal filter (Amicon) and loading into a Shigemi NMR tube for ¹⁹F NMR measurement.

¹⁹F NMR spectra of TFMB-tagged SERCA were acquired on a solution state Bruker 600 MHz Avance NEO spectrometer equipped with a TCI HCN cryoprobe. 1D single-pulse experiments were acquired using a 90° pulse of 12 μs and recycle delay of 0.4 s. Spectra in isotropic bicelles were acquired with 1 k scans and 4 k scans for oriented bicelles. Spectra were processed using NMRPipe⁷.

Oriented solid-state NMR spectroscopy. All ¹⁵N spectra were acquired on a Varian VNMRs spectrometer equipped with a low-*E* static bicelle probe⁸ operating at a ¹H frequency of 700 MHz. 1D [¹H-¹⁵N]-cross-polarization (CP)-based experiments used 90° pulse length of 5 μs, or 50 kHz radiofrequency (RF) field, on ¹H and ¹⁵N channels; contact time of 500 μs with a 10% linear ramp on ¹H centered at 50 kHz; and an acquisition time of 10 ms under 50 kHz SPINAL64 heteronuclear proton decoupling⁹. For all experiments, ¹⁵N was set to 166.3 ppm and externally referenced to ¹⁵NH₄Cl at 39.3 ppm¹⁰; and detected using a spectral width of 100 kHz. 1D [¹H-¹⁵N] water-edited (WE)-CP spectra¹¹ were acquired with a 1.6 ms spin-echo period following an initial 90° pulse on ¹H as a *T*₂-filter to dephase magnetization not belonging to water, then a 100 ms longitudinal mixing period to transfer ¹H polarization from water to protein before the final Hartmann-Hahn¹² CP spin-lock to finally transfer ¹H magnetization to ¹⁵N. 1D [¹H-¹⁵N] rINEPT spectra^{13,14} utilized a 2τ INEPT period of 10.4 ms and an acquisition time of 30 ms under WALTZ16 heteronuclear decoupling¹⁵.

2D separated local field (SLF) spectra were collected using a signal-enhanced (SE)-SAMPI4 experiment¹⁶⁻¹⁸. The indirect dipolar dimension utilized complex points and a spectral width of 20.8 kHz. The *t*₁ evolution period utilized ¹H homonuclear decoupling with an RF field of 50 kHz and 48 μs dwell time, and a phase-switched spin-lock pulses on ¹H and ¹⁵N of 62.5 kHz RF field. The sensitivity enhancement block used a τ delay of 75 μs and three cycles of phase-modulated Lee-Goldberg (PMLG) homonuclear decoupling¹⁹ with an effective RF field of 80 kHz.

3D SE-SAMPI4-PDS spectra²⁰ were acquired with 15 increments in both indirect dimensions; spectral widths of 20.8 kHz and 10 kHz in the dipolar coupling and indirect ¹⁵N dimensions, respectively; and 3 s mixing time for ¹⁵N-¹⁵N diffusion²¹. Total acquisition times for PLN^{AFa} samples were typically 1 h for a 1D [¹H-¹⁵N] CP spectra (1 k scans), 5 h for 1D [¹H-¹⁵N] WE-CP spectra (5 k scans), 24 h for 1D [¹H-¹⁵N] rINEPT spectra (25 k scans), 40 h for 2D SE-SAMPI4 spectra (1 k scans) and 2 weeks for 3D SE-SAMPI4-PDS spectra (2 experiments added with 0.25 k scans each). For the SERCA/PLN^{AFa} complexes, 2D SE-SAMPI4 spectra were acquired over 4.5 days at 25 °C (4 k scans, 15 indirect points)

and 1D [^1H - ^{15}N] CP spectra for 4 h (4 k scans). A recycle delay of 3 sec was used for all experiments. All spectra were processed using NMRPipe⁷ and analyzed using NMRFAM-SPARKY²² and NmrGlue²³.

PISA wheel simulations and fitting. Polar Index Slant Angle (PISA) wheels^{24,25} were fitted to 2D SE-SAMPI4 spectra using the PISA-SPARKY plugin in the NMRFAM-SPARKY package²⁶. Default parameters were used to describe ideal helix structure and ^{15}N chemical shift (CS) and ^{15}N - ^1H dipolar coupling (DC) tensors. The C α -N-H bond angle was modified from 116° to 119° to best fit PLN^{AFA} spectra. CSs and DCs were fit by exhaustively searching tilts (θ), rotations (ρ_{L31} , *i.e.*, referenced to residue Leu31) and order parameters (S) in increments of 0.1° , 1.0° and 0.01, respectively, for the lowest RMSD between calculated and experimental values²⁶. The parameter S , which factors scaling due to rigid-body helical fluctuations and imperfect alignment, was determined as 0.80 ± 0.05 and 0.81 ± 0.03 for PLN^{AFA} and pPLN^{AFA}, respectively, alone in bicelles. Due to the sparsity of peaks assigned for spectra of PLN in complex with SERCA, S was fixed to 0.80 to reduce fitting errors. Errors in tilt θ , ρ_{L31} and S were determined by repeating fitting 20 times with peak positions randomly adjusted at each iteration. Random adjustments were taken from a Gaussian distribution having a standard deviation equal to average FWHM peak linewidths (3 ppm for CS and 0.8 kHz for DC dimensions).

Unrestrained molecular dynamics. A simulation of truncated PLN^{AFA} (M20 to L52; PDB 2LPF²⁷) in 97 DMPC and 32 POPC, 150 mM KCl and 4927 waters was constructed using the CHARMM-GUI webserver^{28,29} and CHARMM36 forcefield³⁰. Production runs were done using the AMBER18^{31,32} package at 10 Å cutoff and 8 Å force-based switching and default configuration files provided by the CHARMM-GUI webserver. For example, using the Langevin thermostat³³ (310 K), Monte Carlo barostat³⁴ (1 bar, semi-isotropic coupling) and the SHAKE algorithm³⁵ for constraining hydrogens. The simulation was run for 1 μs . The final 900 ns of trajectory was used to predict ^{15}N chemical shifts and ^{15}N - ^1H dipolar couplings, as previously reported³⁶.

NMR-restrained refinement of the SERCA/PLN complex. The initial conformation of SERCA in the E2 state was obtained from the crystal structure of the SERCA/PLN complex (PDB 4Y3U)³⁷. Missing loops in the structure of SERCA were introduced using MODELLER software³⁸. The interface between SERCA and PLN^{AFA} (human sequence with a single Asn27Lys substitution) was then refined *in silico* by introducing information from our cross-linking data. Specifically, the transmembrane section of PLN^{AFA}

was docked onto SERCA *in vacuo*, maintaining backbone positional restraints on the pump and restraining the dihedral angles of PLN^{AFA} to retain the helical structure. Docking was guided by cross-linking data³⁹⁻⁴¹, performing short MD runs (500 ps) with an harmonic upper wall potential applied to restrain the distances between cross-linked residues to below 5 Å. 100 such runs were performed starting from different orientations of PLN^{AFA}, and the resulting docked complexes were clustered according to the backbone RMSD of the proteins. The center of the most highly populated cluster was picked as the most representative structure and used to continue the modelling. The N-terminal segment of PLN^{AFA}, not present in the original structure, was built as a random coil detached from SERCA. Ser16 was modelled both with and without the phosphorylation, generating two different PLN^{AFA}/SERCA complexes.

The structures of the PLN^{AFA}/SERCA and pPLN^{AFA}/SERCA complexes were then embedded in DMPC:POPC (3:1) bilayers, mimicking the experimental conditions, and solvated with TIP3P water⁴². The systems were equilibrated for 1 μs with positional restraints using the coarse-grained model MARTINI⁴³ and then re-converted to full-atom descriptions using the Backward approach⁴⁴. The full-atomic systems were equilibrated for 50 ns at 300 K and a further 50 ns after releasing the positional restraints. Eight equally spaced structures were extracted from the final 20 ns of sampling. These eight structures were used as starting points for ssNMR-restrained replica-averaged sampling (RAOR-MD). The final equilibrated box (of dimensions 10.8 x 10.8 x 15.9 nm³) contains 247 DMPC lipids, 82 POPC molecules, 39,017 TIP3P waters and 23 Na⁺ ions to neutralize the system (~174,000 atoms).

¹⁵N chemical shift (CS) and ¹⁵N-¹H dipolar coupling (DC) restraints were incorporated into the sampling using replica-averaged restrained MD, as previously described^{45,46}, composed of eight replicas evolving simultaneously. The restraining forces were gradually incorporated during an initial equilibration phase of 20 ns, where the forces were linearly increased to a maximum of 50 J/(mol·ppm²) and 800 J/(mol·kHz²) for CSs and DCs, respectively.

In order to enhance the conformational sampling of the disordered domain Ia of PLN^{AFA}, we implemented a sampling based on annealing cycles, whereby the PLN^{AFA} N-terminus periodically binds and detaches from the SERCA surface. The experimental PRE measurements⁴⁷ were incorporated in order to drive each binding event. At the beginning of each cycle, the domain Ia of PLN^{AFA} is fully detached from SERCA by introducing a lower-wall harmonic potential that pushes PLN^{AFA} residues away from SERCA residues present in the cytoplasmic domains of the pump. The lower wall potential pushes PLN^{AFA} residues 0 to 10 at least 50 Å away from Ile140 (SERCA A domain), Thr430 (SERCA N domain)

and Cys674 (SERCA P domain). Residues 11 to 14 were pushed at least 25 Å away from those residues and in addition the interfacial SERCA residues Thr742, Ala327 and Leu119. The detachment occurs gradually, by linearly increasing the force of the lower-wall potential to a maximum of 5 J/(mol · nm²) after 500 ps. During this time, the temperature is also linearly increased to 370 K to enhance the conformational sampling space of the disordered domain Ia. CS and DC force constants were linearly decreased to half their value to avoid instabilities during this high-energy phase of the cycle. This detachment step yields a fully detached PLN^{AFA} domain Ia with no SERCA contacts and enough surrounding free space to explore its unbound disordered conformational space. This step is followed by another 500 ps of sampling at 370 K, where the detached PLN^{AFA} domain Ia is allowed to fluctuate. Subsequently, a binding stage follows, whereby the lower-wall potential is linearly removed over 1 ns of sampling. The PRE-derived distance restraints were gradually incorporated over this time as an upper-wall potential at 30 Å with a maximum force of 5 J/(mol · nm²). During this step the force constants of CS and DC are also restored to their full value, and the temperature is linearly decreased to 300 K. After the binding phase, the PLN^{AFA} N-terminus adopts a SERCA-bound conformation. This step leads onto the sampling phase of the cycle, where the restraint forces and the temperature are kept constant for 2 ns. The structures sampled during these 2 ns are the ones included in the final conformational ensembles of SERCA/PLN^{AFA}. This annealing cycle sampling approach is illustrated in Extended Data Fig. 13.

We performed 25 annealing cycles per replica for both PLN^{AFA} and pPLN^{AFA}, resulting in a total simulation time of 0.8 μs for each ensemble. 10,000 equally separated structures in the sampling part of the cycles were extracted to perform the analyses described in the main text. All samplings were performed using a previously described version of GROMACS⁴⁸, modified to include the CS and DC restraints⁴⁶. The CHARMM36 force field³⁰ was used. Temperature was coupled using the v-rescale algorithm⁴⁹ and pressure was coupled at 1 bar using the semi-isotropic Berendsen method⁵⁰. All simulations were carried out under periodic boundary conditions. The integration timestep was set to 2 fs and the LINCS algorithm was used for constraints⁵¹. Electrostatic interactions were accounted for using the Particle Mesh Ewald method⁵². Ensembles were analyzed using CPPTraj⁵³ for principle component analyses (PCA); VMD⁵⁴ for contact, hydrogen bond and distance measurements; custom Python scripts for computing helical tilt (θ) and rotation (ρ) angles; and GROMACS energy tool for electrostatic interactions.

Extended data figures and tables

Extended Data Fig. 1: Assignment by 3D OS-ssNMR. a, 2D projection and **b**, strip plot of [^{15}N - ^{15}N - ^1H] 3D SE-SAMPI4-PDSD spectrum of pPLN^{AF} in bicelles showing sequential ^{15}N - ^{15}N correlations.

Extended Data Fig. 2: Assignment of OS-ssNMR spectra by selective labeling and un-labeling experiments. 2D [^{15}N - ^1H] SE-SAMPI4 spectra of uniformly ^{15}N -labelled PLN^{AFA} (blue) and pPLN^{AFA} (red) overlaid with recombinant residue-specific uniformly labeled (U) and uniformly unlabeled (UL) preparations (black). Circles indicate theoretical peak positions based on PISA fitting and labels in *italics* are residues missing from experimental spectra.

Extended Data Fig. 3: OS-ssNMR prediction of SLF spectra by unrestrained MD simulation. Unrestrained 1 μs of MD simulation of truncated PLN^{AFA} (M20 to L52; PDB 2LPF²⁷) embedded in a DMPC/POPC bilayer showing **a**, the back-calculated SLF spectrum of domain Ib (red) and II (blue) residues computed as previously described³⁶, **b**, PLN^{AFA} domain II tilt angle throughout the simulation and **c**, the corresponding histogram.

Extended Data Fig. 4: Synthesis and oriented NMR of the trifluoromethylbenzyl (TFMB)-methanethiosulfonate (MTS) tag. **a**, Synthesis of the TFMB-MTS tag. Lettering specifies carbon and proton assignments in **b**, ^1H and **c**, ^{13}C NMR spectra of the tag in CDCl_3 . Values in parenthesis specify peak multiplicity (s = singlet, d = doublet, q = quartet). **d**, ^{19}F NMR of TFMB-tagged SERCA in isotropic bicelles. **e**, ^{19}F NMR of TFMB-tagged SERCA (black) and free tag (red) in oriented bicelles. Spectra show that the tag partitions into bicelles, but with considerably reduced dipolar coupling compared to SERCA-reacted tag. This confirms that the dipolar triplet is not from unreacted tag.

Extended Data Fig. 5: Restraints for RAOR-MD structural refinement. **a**, Schematic of crosslinking restraints³⁹⁻⁴¹ used for docking and paramagnetic relaxation enhancements previously observed by MAS-ssNMR⁴⁷ between methanethiosulfonate spin-labeled (MTSSL) Cys674 and cytoplasmic residues of PLN^{AFA} and pPLN^{AFA}. **b**, Averaged pairwise distances between cytoplasmic residues (at C β) of PLN^{AFA} and Cys674-Sy show qualitative agreement with **c**, prior [^{13}C - ^{13}C] DARR MAS-ssNMR PRE measurements⁴⁷. **d**, Wave plots comparing ^{15}N chemical shifts and ^{15}N - ^1H dipolar couplings obtained experimentally (blue or red circles) and back-calculated (green triangles) from RAOR-MD ensembles. Wave lines were taken from a PISA fits to the experimental points. **e**, Tilt (θ) and azimuthal angles (ρ_{31}) back-calculated from RAOR-MD ensembles of PLN^{AFA} (blue) and pPLN^{AFA} (red). **f**, REMD pairwise distance distributions (C β -C β) of crosslinking residues^{39-41,55,56}. Histograms encased in dotted lines relate to residue-pairs restrained during initial docking. Shaded regions show a typical 4 to 15 Å crosslinking range. The residue pair Asn30 – Cys318, outside of this range, has optimal crosslinking with longer (15 Å) reagents⁵⁵.

Extended Data Fig. 8: RAOR-MD clustering. Top 20 most representative structures of each cluster extracted from PCA. Structures were aligned by TM residues of SERCA. Only the most representative structure of SERCA is shown for each cluster.

Extended Data Fig. 9: Example open state snapshot (PCA cluster 6) of SERCA stabilized by electrostatic interactions between pSer16 and the N domain.

Extended Data Fig. 10: Correlation of inhibitory TM contacts with formation of the non-inhibitory B-state. a, Per-residue ensemble-averaged intermolecular contacts for TM helices of SERCA. A single contact by SERCA to PLN^{AFA} (blue) or pPLN^{AFA} (red) in RAOR-MD simulations is defined when any SERCA atom comes within 3.5 Å of any PLN atom for any given frame. Total contacts were accumulated by residue and the averages for each calculation was determined over 10000 frames. PLN^{AFA} residues responsible for the most contacts are designated at local maxima.

Extended Data Fig. 11: Effects of Ca^{2+} binding to SERCA on the topology of PLN and pPLN. **a, b**, 2D ^{15}N - ^1H SE-SAMPI4 spectrum of PLN^{AFA} (**a**) and pPLN^{AFA} (**b**) bound to SERCA in the E1 form reconstituted into aligned lipid bicelles. PISA wheels for an ideal helix $[(\phi, \psi)=(-63^\circ, -42^\circ)]$ are superimposed. Equivalent spectra of the E2 form complexes are shown in grey. **c**, The conformational and topological effects of phosphorylation and Ca^{2+} binding to the SERCA/PLN^{AFA} complex.

309

310 **Extended Data Fig. 12: Activity and confirmation of PLN^{AFA}.** **a**, SDS-PAGE gel of the expression and purification of
311 PLN^{AFA} as an MBP-fusion: ladder (L), pre-induced (PI) and induced (I) expression, lysate supernatant (Lys.), purified MBP-
312 PLN^{AFA} eluted from amylose resin (E), MBP-PLN^{AFA} after cleavage with TEV protease (C), and HPLC-purified PLN^{AFA}. **b**,
313 MALDI-MS spectra of HPLC-purified ¹⁵N PLN^{AFA} and pPLN^{AFA}. **c**, Coupled-enzyme ATPase activity assays of SERCA
314 reconstituted into DMPC/POPC (4:1; lipid-to-protein ratio of 700:1) liposomes with a 5-fold excess of either PLN^{AFA} or
315 pPLN^{AFA}. Assays consisted of 50 mM HEPES, 100 mM KCl, 5 mM MgCl₂, 0.2 mM NADH, 0.5 mM PEP, 10 U/mL pyruvate
316 kinase, 10 U/mL lactate dehydrogenase, and 7 μM calcium ionophore A23187 at pH 7.0. ATPase activity was measured by the
317 rate of reduction in NADH absorbance at 340 nm at EGTA-buffered calcium concentrations between 10⁻⁷ and 10⁻⁴ M, initiated
318 by addition of 0.5 mM ATP. Activity as a function of calcium concentration was fitted to a Hill function to extract the pK_{Ca}
319 values (calcium concentration at half V_{max}) shown. Errors indicate the standard deviation from 3 replicate measurements. **d**,
320 SDS-PAGE gel of SERCA and PLN reconstituted into bicelles for OS-ssNMR: bicelle sample freshly solubilized by DHPC
321 (B), supernatant after centrifugation (S) and pellet formed from a small non-solubilized component (P).

322

Fig. 13: Annealing cycle used in the sampling of the SERCA/PLN^{AFA} complex. During the first nanosecond of the simulation, the N-terminus of PLN is detached from SERCA and the temperature is raised to 370 K to randomize its conformation. Then the system is cooled back down to 300 K over 1 ns, during which time the CS, DC and PRE restraints are re-introduced. The complex is sampled for 2 ns, after which the cycle restarts.

Table 1: OS-ssNMR assignments. Summarized ¹⁵N CS and ¹⁵N-¹H DC assignments of PLN^{AFA} and pPLN^{AFA} reconstituted alone in bicelles or in complex with SERCA in either E2 (Ca²⁺-free) or E1 (5 mM Ca²⁺) states.

Res.	PLN ^{AFA}		pSer16-PLN ^{AFA}		PLN ^{AFA} + SERCA (E2)		pSer16-PLN ^{AFA} + SERCA (E2)		PLN ^{AFA} + SERCA (E1)		pSer16-PLN ^{AFA} + SERCA (E1)	
	CS	DC	CS	DC	CS	DC	CS	DC	CS	DC	CS	DC
N27	117.6*	1.19*	118.1	0.90	-	-	-	-	-	-	-	-
N30	117.6*	1.19*	121.5	3.10	-	-	-	-	-	-	-	-
L31	152.8	0.94	155.2	0.74	-	-	164.3	1.26	-	-	-	-
F32	167.7	2.46	177.9	3.38	-	-	187.6	4.07	181.6	3.78	186.6	4.56
N34	125.8	1.36	132.4	2.71	-	-	-	-	-	-	-	-
F35	164.7	1.17	166.2*	1.36*	-	-	179.1	2.86	176.4	2.30	-	-
A36	176.5	4.74	184.3	5.28	186.5	5.72	191.0	6.37	190.4	5.91	192.8	6.76
L37	123.9	4.89	132.2	5.71	136.5	6.66	146.0	6.57	146.1	4.73	151.7	5.87
I38	140.8	1.03	146.5	1.40	156.9	1.86	160.3	2.54	156.4	2.11	164.9	2.14
L39	181.7*	2.31*	185.7*	2.86*	190.3	3.88	194.4	3.99	194.5	3.76	198.5	4.75
I40	155.7	6.19	163.5*	6.88*	164.0	7.04	171.5	6.87	166.7	6.99	169.9	7.25
F41	127.8	3.39	134.6	4.19	-	-	150.0	4.46	-	-	148.4	4.33
L42	160.5	0.91	166.2*	1.36*	175.5	1.74	179.1	2.86	-	-	181.1	2.63

L43	187.5*	4.17*	190.9*	4.46*	192.8	5.77	198.3	5.76	196.5	5.89	-	-
L44	138.0	6.02	145.6	6.19	149.9	6.22	155.5	6.26	156.0	5.19	155.1	6.65
I45	139.2	1.80	144.5	2.64	152.7	2.74	160.3	2.54	-	-	162.1	3.57
A46	181.7*	2.31*	185.7*	2.86*	-	-	191.4	2.84	-	-	-	-
I47	170.5	6.35	175.9	6.65	-	-	181.8	7.23	179.5	6.74	181.9	7.99
I48	132.7	4.88	139.2	5.39	145.5	5.16	154.3	6.03	151.2	4.94	-	-
V49	157.1	1.75	160.1	2.26	-	-	-	-	-	-	-	-
M50	187.5*	4.17*	190.9*	4.46*	-	-	198.0	5.14	202.5	4.80	199.9	5.94
L51	158.3	7.06	163.5*	6.88*	-	-	-	-	-	-	-	-

* These peaks are overlapped.

Table 2: Pairwise inter- and intramolecular hydrogen bond summary for PLN^{AFA}/SERCA REMD PCA clusters. Parentheses report the average number hydrogen bonds to a charged residue of SERCA or PLN (bold font) observed over all frames assigned to the respective clusters. Hydrogen bonds were defined with a donor -acceptor distance less than 3 Å and a donor-H-acceptor angle less than 20°.

Cluster	Average hydrogen bonds per frame						
	E2	K3	R9	R13	R14	S16	E19
1	R556 (0.10) K365 (0.08) R638 (0.02)	-	E606 (0.05)	E19 (0.01)	E606 (0.01)	-	K328 (0.08) R13 (0.01)
2	R556 (0.10) K365 (0.04)	E644 (0.02) D557 (0.02)	D557 (0.01)	E606 (0.05) E19 (0.04)	E606 (0.02)	-	K328 (0.38) R13 (0.04)
3	K365 (0.11) R556 (0.09) R638 (0.01)	D399 (0.01)	E606 (0.02)	-	E606 (0.06)	-	K328 (0.15) R325 (0.04) K329 (0.03)
4	K397 (0.14) K365 (0.11) R638 (0.05)	D399 (0.24)	D557 (0.10) E392 (0.02) E606 (0.01)	D616 (0.06)	-	-	-

Table 3: Pairwise inter- and intramolecular hydrogen bond summary for pSer16-PLN^{AFA}/SERCA REMD PCA clusters. Hydrogen bonds were measured according to Table 2.

Cluster	Average hydrogen bonds per frame						
	E2	K3	R9	R13	R14	S16	E19
1	K365 (0.04) R556 (0.03) K397 (0.02)	D557 (0.01)	D557 (0.14) S16 (0.13) E392 (0.02)	S16 (0.59) E606 (0.02)	S16 (0.72) E606 (0.04)	R14 (0.72) R13 (0.59) R604 (0.54) K605 (0.30)	K328 (0.07)

						R9 (0.13)	K329 (0.02)
2	K365 (0.07) R556 (0.03)	D399 (0.01)	S16 (0.55) E606 (0.03)	S16 (0.21) E19 (0.06) E748 (0.02) D616 (0.01)	S16 (0.81) E606 (0.06)	R14 (0.81) R9 (0.55) R13 (0.21) K605 (0.16) R604 (0.01)	K328 (0.10) R13 (0.06)
3	K365 (0.12) K3 (0.02) R556 (0.01)	D399 (0.03) D557 (0.02) E2 (0.02)	S16 (0.82) E606 (0.05)	S16 (0.07) E748 (0.03)	S16 (0.85) E606 (0.01)	R14 (0.85) R9 (0.82) R13 (0.07) K605 (0.05)	-
4	R556 (0.09) K365 (0.06) R560 (0.02) R638 (0.01) K400 (0.01)	D557 (0.03)	S16 (0.28) E606 (0.05)	S16 (0.57) E19 (0.03)	S16 (0.86) E606 (0.02)	R14 (0.86) R13 (0.57) R9 (0.28)	K328 (0.09) R13 (0.03)
5	R556 (0.07) K365 (0.05) K3 (0.03) K400 (0.03) R638 (0.03)	399 (0.04) E2 (0.03)	S16 (0.16) E606 (0.05)	S16 (0.77)	S16 (0.77)	R13 (0.77) R14 (0.77) R9 (0.16) K328 (0.03) K329 (0.02)	K328 (0.13) K464 (0.02)
6	R556 (0.06) K3 (0.04)	E2 (0.04)	D399 (0.08) E394 (0.05)	S16 (0.84)	S16 (1.14) E392 (0.25)	R14 (1.14) R460 (0.89) R13 (0.84) K464 (0.11) K329 (0.07) R325 (0.01)	K328 (0.21) K329 (0.04) K464 (0.03)
7	K365 (0.14)	-	E19 (0.03) D616 (0.02)	E748 (0.54) E606 (0.03)	S16 (0.36)	R325 (1.18) R14 (0.36) K329 (0.31) K328 (0.25)	R9 (0.03)
8	K397 (0.10) K400 (0.03)	E644 (0.01)	E394 (0.23)	S16 (0.67)	S16 (1.22) E392 (0.65)	R14 (1.22) R13 (0.67) R460 (1.35)	R325 (0.45) K328 (0.44) K329 (0.37)

References

- 1 Buck, B. *et al.* Overexpression, purification, and characterization of recombinant Ca-ATPase regulators for high-resolution solution and solid-state NMR studies. *Protein Expression Purif.* **30**, 253-261, (2003).
- 2 Lacabanne, D., Meier, B. H. & Böckmann, A. Selective labeling and unlabeled strategies in protein solid-state NMR spectroscopy. *J. Biomol. NMR* **71**, 141-150, (2018).

- 348 3 Reddy, L. G., Cornea, R. L., Winters, D. L., McKenna, E. & Thomas, D. D. Defining the Molecular
349 Components of Calcium Transport Regulation in a Reconstituted Membrane System. *Biochemistry*
350 **42**, 4585-4592, (2003).
- 351 4 Stokes, D. L. & Green, N. M. Three-dimensional crystals of CaATPase from sarcoplasmic
352 reticulum. Symmetry and molecular packing. *Biophys. J.* **57**, 1-14, (1990).
- 353 5 Vostrikov, V. V. *et al.* Ca(2+) ATPase Conformational Transitions in Lipid Bilayers Mapped by
354 Site-directed Ethylation and Solid-State NMR. *ACS chemical biology* **11**, 329-334, (2016).
- 355 6 Weber, D. K. *et al.* Cysteine-ethylation of tissue-extracted membrane proteins as a tool to detect
356 conformational states by solid-state NMR spectroscopy. *Methods Enzymol.* **621**, 281-304, (2019).
- 357 7 Delaglio, F. *et al.* NMRPipe: A multidimensional spectral processing system based on UNIX
358 pipes. *J. Biomol. NMR* **6**, 277-293, (1995).
- 359 8 Gor'kov, P. L. *et al.* Using low-E resonators to reduce RF heating in biological samples for static
360 solid-state NMR up to 900 MHz. *J. Magn. Reson.* **185**, 77-93, (2007).
- 361 9 Fung, B. M., Khitrin, A. K. & Ermolaev, K. An Improved Broadband Decoupling Sequence for
362 Liquid Crystals and Solids. *J. Magn. Reson.* **142**, 97-101, (2000).
- 363 10 Bertani, P., Raya, J. & Bechinger, B. ¹⁵N chemical shift referencing in solid state NMR. *Solid*
364 *State Nucl. Magn. Reson.* **61–62**, 15-18, (2014).
- 365 11 Dicke, A., Gopinath, T., Wang, Y. & Veglia, G. Probing Residue-Specific Water–Protein
366 Interactions in Oriented Lipid Membranes via Solid-State NMR Spectroscopy. *J. Phys. Chem. B*
367 **120**, 10959-10968, (2016).
- 368 12 Hartmann, S. R. & Hahn, E. L. Nuclear Double Resonance in the Rotating Frame. *Phys. Rev.* **128**,
369 2042-2053, (1962).
- 370 13 Gopinath, T. & Veglia, G. Probing membrane protein ground and conformationally excited states
371 using dipolar- and J-coupling mediated MAS solid state NMR experiments. *Methods* **148**, 115-
372 122, (2018).
- 373 14 Nelson, S. E. D. *et al.* Effects of the Arg9Cys and Arg25Cys mutations on phospholamban's
374 conformational equilibrium in membrane bilayers. *Biochim. Biophys. Acta* **1860**, 1335-1341,
375 (2018).
- 376 15 Shaka, A. J., Keeler, J., Frenkiel, T. & Freeman, R. An improved sequence for broadband
377 decoupling: WALTZ-16. *J. Magn. Reson.* **52**, 335-338, (1983).

- 378 16 Gopinath, T. & Veglia, G. Sensitivity enhancement in static solid-state NMR experiments via
379 singleand multiple-quantum dipolar coherences. *J. Am. Chem. Soc.* **131**, 5754-5756, (2009).
- 380 17 Gopinath, T., Verardi, R., Traaseth, N. J. & Veglia, G. Sensitivity enhancement of separated local
381 field experiments: Application to membrane proteins. *J. Phys. Chem. B* **114**, 5089-5095, (2010).
- 382 18 Nevzorov, A. A. & Opella, S. J. Selective averaging for high-resolution solid-state NMR
383 spectroscopy of aligned samples. *J. Magn. Reson.* **185**, 59-70, (2007).
- 384 19 Vinogradov, E., Madhu, P. K. & Vega, S. High-resolution proton solid-state NMR spectroscopy
385 by phase-modulated Lee-Goldburg experiment. *Chem. Phys. Lett.* **314**, 443-450, (1999).
- 386 20 Mote, K. R. *et al.* Multidimensional oriented solid-state NMR experiments enable the sequential
387 assignment of uniformly ¹⁵N labeled integral membrane proteins in magnetically aligned lipid
388 bilayers. *J. Biomol. NMR* **51**, 339-346, (2011).
- 389 21 Traaseth, N. J., Gopinath, T. & Veglia, G. On the performance of spin diffusion NMR techniques
390 in oriented solids: Prospects for resonance assignments and distance measurements from separated
391 local field experiments. *J. Phys. Chem. B* **114**, 13872-13880, (2010).
- 392 22 Lee, W., Tonelli, M. & Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular
393 NMR spectroscopy. *Bioinformatics* **31**, 1325-1327, (2015).
- 394 23 Helmus, J. J. & Jaroniec, C. P. Nmrglue: an open source Python package for the analysis of
395 multidimensional NMR data. *J. Biomol. NMR* **55**, 355-367, (2013).
- 396 24 Denny, J. K., Wang, J., Cross, T. A. & Quine, J. R. PISEMA powder patterns and PISA wheels.
397 *J. Magn. Reson.* **152**, 217-226, (2001).
- 398 25 Marassi, F. M. & Opella, S. J. A Solid-State NMR Index of Helical Membrane Protein Structure
399 and Topology. *J. Magn. Reson.* **144**, 150-155, (2000).
- 400 26 Weber, D. K., Wang, S., Markley, J. L., Veglia, G. & Lee, W. PISA-SPARKY: an interactive
401 SPARKY plugin to analyze oriented solid-state NMR spectra of helical membrane proteins.
402 *Bioinformatics*, 1-2, (2020).
- 403 27 De Simone, A. *et al.* Structures of the Excited States of Phospholamban and Shifts in Their
404 Populations upon Phosphorylation. *Biochemistry* **52**, 6684-6694, (2013).
- 405 28 Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: A web-based graphical user interface for
406 CHARMM. *J. Comput. Chem.* **29**, 1859-1865, (2008).
- 407 29 Wu, E. L. *et al.* CHARMM-GUI Membrane Builder toward realistic biological membrane
408 simulations. *J. Comput. Chem.* **35**, 1997-2004, (2014).

- 409 30 Huang, J. & MacKerell, A. D. CHARMM36 all-atom additive protein force field: Validation based
410 on comparison to NMR data. *J. Comput. Chem.* **34**, 2135-2145, (2013).
- 411 31 AMBER18 (University of California, San Francisco, 2018).
- 412 32 Crowley, M. F., Williamson, M. J. & Walker, R. C. CHAMBER: Comprehensive support for
413 CHARMM force fields within the AMBER software. *Int. J. Quantum Chem* **109**, 3767-3772,
414 (2009).
- 415 33 Loncharich, R. J., Brooks, B. R. & Pastor, R. W. Langevin dynamics of peptides: The frictional
416 dependence of isomerization rates of N-acetylalanyl-N'-methylamide. *Biopolymers* **32**, 523-535,
417 (1992).
- 418 34 Faller, R. & de Pablo, J. J. Constant pressure hybrid Molecular Dynamics–Monte Carlo
419 simulations. *The Journal of Chemical Physics* **116**, 55-55, (2002).
- 420 35 Miyamoto, S. & Kollman, P. A. Settle: An analytical version of the SHAKE and RATTLE
421 algorithm for rigid water models. *J. Comput. Chem.* **13**, 952-962, (1992).
- 422 36 Weber, D. K. & Veglia, G. A Theoretical Assessment of the Structure Determination of Multi-
423 Span Membrane Proteins by Oriented Sample Solid-State NMR Spectroscopy. *Aust. J. Chem.* **73**,
424 246-251, (2019).
- 425 37 Akin, B. L., Hurley, T. D., Chen, Z. & Jones, L. R. The Structural Basis for Phospholamban
426 Inhibition of the Calcium Pump in Sarcoplasmic Reticulum. *J. Biol. Chem.* **288**, 30181-30191,
427 (2013).
- 428 38 Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. *Curr. Protocol.*
429 *Protein Sci.* **86**, 2.9.1-2.9.37, (2016).
- 430 39 Chen, Z., Akin, B. L., Stokes, D. L. & Jones, L. R. Cross-linking of C-terminal residues of
431 phospholamban to the Ca²⁺ pump of cardiac sarcoplasmic reticulum to probe spatial and
432 functional interactions within the transmembrane domain. *J. Biol. Chem.* **281**, 14163-14172,
433 (2006).
- 434 40 Chen, Z., Stokes, D. L., Rice, W. J. & Jones, L. R. Spatial and Dynamic Interactions between
435 Phospholamban and the Canine Cardiac Ca²⁺ Pump Revealed with Use of Heterobifunctional
436 Cross-linking Agents. *J. Biol. Chem.* **278**, 48348-48356, (2003).
- 437 41 Toyoshima, C. *et al.* Modeling of the inhibitory interaction of phospholamban with the Ca²⁺
438 ATPase. *Proc. Natl. Acad. Sci. USA* **100**, 467-472, (2003).

- 439 42 Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of
440 simple potential functions for simulating liquid water. *J. Chem. Phys.* **79**, 926-935, (1983).
- 441 43 Marrink, S. J., Risselada, H. J., Yefimov, S., Tieleman, D. P. & de Vries, A. H. The MARTINI
442 Force Field: Coarse Grained Model for Biomolecular Simulations. *J. Phys. Chem. B* **111**, 7812-
443 7824, (2007).
- 444 44 Wassenaar, T. A., Pluhackova, K., Böckmann, R. A., Marrink, S. J. & Tieleman, D. P. Going
445 Backward: A Flexible Geometric Approach to Reverse Transformation from Coarse Grained to
446 Atomistic Models. *J. Chem. Theory Comput.* **10**, 676-690, (2014).
- 447 45 De Simone, A., Mote, K. R. & Veglia, G. Structural Dynamics and Conformational Equilibria of
448 SERCA Regulatory Proteins in Membranes by Solid-State NMR Restrained Simulations. *Biophys.*
449 *J.* **106**, 2566-2576, (2014).
- 450 46 Sanz-Hernández, M., Vostrikov, V. V., Veglia, G. & De Simone, A. Accurate Determination of
451 Conformational Transitions in Oligomeric Membrane Proteins. *Sci. Rep.* **6**, 23063-23063, (2016).
- 452 47 Gustavsson, M. *et al.* Allosteric regulation of SERCA by phosphorylation-mediated
453 conformational shift of phospholamban. *Proc. Natl. Acad. Sci. USA* **110**, 17338-17343, (2013).
- 454 48 Pronk, S. *et al.* GROMACS 4.5: A high-throughput and highly parallel open source molecular
455 simulation toolkit. *Bioinformatics* **29**, 845-854, (2013).
- 456 49 Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. *J. Chem.*
457 *Phys.* **126**, 014101-014101, (2007).
- 458 50 Berendsen, H. J. C., Postma, J. P. M., Van Gunsteren, W. F., Dinola, A. & Haak, J. R. Molecular
459 dynamics with coupling to an external bath. *J. Chem. Phys.* **81**, 3684-3690, (1984).
- 460 51 Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint solver
461 for molecular simulations. *J. Comput. Chem.* **18**, 1463-1472, (1997).
- 462 52 Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N·log(N) method for Ewald sums
463 in large systems. *J. Chem. Phys.* **98**, 10089-10092, (1993).
- 464 53 Roe, D. R. & Cheatham, T. E. PTRAJ and CPPTRAJ: Software for Processing and Analysis of
465 Molecular Dynamics Trajectory Data. *J. Chem. Theory Comput.* **9**, 3084-3095, (2013).
- 466 54 Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. *J. Mol. Graphics* **14**,
467 33-38, (1996).

- 468 55 Jones, L. R., Cornea, R. L. & Chen, Z. Close Proximity between Residue 30 of Phospholamban
 469 and Cysteine 318 of the Cardiac Ca²⁺ Pump Revealed by Intermolecular Thiol Cross-linking. *J.*
 470 *Biol. Chem.* **277**, 28319-28329, (2002).
- 471 56 James, P., Inui, M., Tada, M., Chiesi, M. & Carafoli, E. Nature and site of phospholamban
 472 regulation of the Ca²⁺ pump of sarcoplasmic reticulum. *Nature* **342**, 90-92, (1989).
- 473